IN THIS ISSUE

Chemical Evaluation Of The Functions Of The Liver, Part I
John G. Reinhold..................................................... page 82

A Note On Quantitative Urobilinogen Determinations
Bernard Balikov..................................................... page 89

Review Of Current Literature.................................... page 90

Publishers' Corner.................................................. page 93

Guide To Ethics Governing The Conduct Of Clinical Chemists........ page 94
THE SECRETARY REPORTS

At the time this issue of THE CLINICAL CHEMIST makes its appearance, the AACC will have completed its first five years. The rapid growth of the Association in this relatively short period is an acknowledgement of the need for such an organization as ours.

Various objectives of the Association set up in the first stages have either already been satisfactorily completed or else well under way. The foremost accomplishment is the evolution of THE CLINICAL CHEMIST from a small newsletter to that of a responsible journal. "Standard Methods!" is finding a useful place in the laboratory, with subsequent volumes in preparation. The Ernest Bischoff Award has been established as an outstanding annual event. A Code Of Ethics is now part of our governing principles. Other progress notes have frequently been noted in these columns.

The once phase of Association activity that has not been fully explored is the formation of local sections. The ideal organizational arrangement for us would probably be that of various autonomous local groups consolidated into a cohesive national body. Not the least in importance of local groups is the matter of legislation as it pertains to clinical chemistry, which cannot be properly dealt with from national headquarters. Those people from one State will not benefit from adequate laws governing clinical chemistry in another State. Legislators throughout the country are being made aware of the laboratory problems and they must be alerted to the fact that the public will be better served by high standards in clinical chemistry. Local sections are in the best position to do that.

The membership of the AACC is widely distributed and yet only six local sections are in operation at this time, of which four are along the northeast coast. The other two are Chicago and Southern California. Formation of local sections can only be realized by the initiative of the members in any area.

Max M. Friedman National Secretary

PHILADELPHIA SECTION

The first meeting of the 1953-54 season of the Philadelphia Section, American Association of Clinical Chemists, was held at 8:00 p.m. on Tuesday, October 27, 1953, in the North Lecture Room of the Graduate Hospital of the University of Pennsylvania. Prior to the meeting, there was an informal dinner in honor of the speaker at the Homestead Restaurant.

The President, Mr. A. G. Keller, introduced Dr. David Seligson, Director of the Division of Biochemistry at the Graduate Hospital who spoke on "The Measurement of Chlorides in Biological Fluids and a New Method for the Measurement of Chlorides".

With due consideration to their limitations, as well as to their advantages, Dr. Seligson described the techniques for chlorides determination which are now commonly used in clinical laboratories. He then described an electrometric titration for chloride analysis which has been developed at the Graduate Hospital. After the lecture, Dr. Seligson kindly consented to answer questions related to his subject. At the conclusion of the formal meeting, the group adjourned to the laboratories of the Graduate Hospital for a demonstration of the technique.

BOSTON SECTION

The Boston Section held its first meeting of the current season on October 21st at the New England Center Hospital.

Annual election of officers were held at this time, the following were elected:

Chairman—Arthur DeTore: Sias Laboratories

Chairman——— Arthur DeTore: Sias Laboratories

Vice-Chairman—Joseph Annino: Massachusetts Memorial Hospital

Sec. Treasurer—Esther Thomas: New England Center Hospital

The speaker of the evening was Joseph Benotti of the Boston Medical Laboratory whose subject was "Protein-Bound Iodine, and its Relation to Total Iodine."

Protein-Bound Iodine (PBI) according to the speaker, and to a rapidly growing literature, constitutes a valuable criterion in evaluating thyroid pathology. According to some, the PBI now is considered a more reliable test than radio-iodine uptake, and more sensitive an indicator than the serum cholesterol or BMR.

Mr. Benotti reviewed the methods of more recent years for determining PBI; mentioning those of Chaney, Barker, and Zak, all of which depend ultimately on the catalysis by iodine of the yellow cationic ion to the colorless cationic ion. In his own laboratory, the speaker uses the method of Zak.

Basing his opinion on hundreds of PBI's done at his laboratory, the speaker dealt at length with the importance of simultaneous Total Iodine determinations on each specimen. This is done simply by omitting protein precipitation with trichloroacetic acid. Greater significance is given to the PBI, he explained, since iodine in varied form is often used in medication. If the iodine contaminant is inorganic (Lugol's, hydriodic acid) it is generally possible to wash it from the protein precipitate during the early stages of the determination.

Foreign iodine administered in organic form, as in such x-ray contrast
QUID NUNCIS

ALBERT E. SOBEL, past president of the AACC has just completed a group of lectures on the chemistry of bone and tooth formation before local sections of the ACS. Dr. Sobel was guest speaker at meetings of the Penn.-N.Y. Western Border, Penn.-Ohio Border, Columbus, Wooster, Northeaster Ohio and Akron Sections of the American Chemical Society.

**************

Dr. Joseph Greenspan announces that his company, Process And Instruments are now situated in larger quarters. The new address is, 15 Stone Avenue, Brooklyn 33, N.Y.

**************

ALEXANDER T. SHULGIN, formerly a member of the Biochemistry Department of the University of California at Berkeley, becomes director of the Radiochemical Division, BIO-RAD Laboratories, Berkeley, California. Prior to his faculty position at the University, he attended Harvard University and the University of California. His work and publications have been in the field of isotopic organic syntheses for investigation of metabolic processes.

In his new post, Dr. Shulgin will be responsible for technical operations concerned with production of the Laboratories’ specialized line of radiochemicals for the biological and medical fields.

---

media as lipiodol or diodrast, may cause greater difficulty the speaker explained. In the latter cases, the iodine may be in some way incorporated with protein, so that analytically it may respond as PBI. In these cases, the Total Iodine may be as much as 20 or more micrograms %, with an appreciable difference between it and the PBI. Normally the speaker stated, the PBI and Total Iodine are either the same, or at most 1 or 2 micrograms % apart from each other. A greater divergence than this, together with a high Total Iodine, should cast some doubt on the diagnostic value of the PBI.

---

CONSTANT TEMPERATURE BATH

Operating Sensitivity ±20.5°C

CONSTANT TEMPERATURE BATH for Prothrombin Test, Electric. A modification of an assembly suggested by A. E. Meyer and R. S. Overman in the laboratory of The Malline Co. Working range +30 to +60°C, with operating sensitivity of ±0.5°C. Consisting of Pyrex brand glass jar, 10 inches high x 10-1/8 inches diameter, 200-watt immersion heater, variable speed electric stirrer, with adjustable chuck and metal propeller, mounted on the side wall of the glass jar, thermometer +30 to 70°C in 0.2°C, Penval Thermorregulator, neca pilot lamp, plug-in type, test tube support of copper which fits on the rim of the jar and which contains 27 holes 9/16-inch diameter and 18 holes 7/16-inch diameter, for suspending tubes in the bath, and three aluminum clamps.

9925-F. Constant Temperature Bath for Prothrombin Test, Electric, as above described, power consumption approx. 210 watts. With cord connector, three-way tap, wiring and cap for attaching heater and thermostatic regulator to line. For 115 volts, 60 cycles, a.c. .................... $1.90

9927-F. Platform, Semi-circular, of Stainless steel, as shown in illustration of 9928-A; for use in above bath in place of the test tube rack for supporting flasks, beakers, etc. .................. 12.00

---

CONSTANT TEMPERATURE BATH

CONSTANT TEMPERATURE BATH, Circular, A.H.T. Co. Specification. Offers advantages of full visibility and ample unobstructed working space for a variety of work in the clinical laboratory, with a sensitivity of ±0.5°C or better in the range to 60°C. A semi-circular platform, adjustable in height from 3 to 8 inches, supports test tube racks, flasks, beakers, etc. Consisting of a Pyrex brand glass jar, 12 x 12 inches, top plate with control box, single speed electric stirring device with Monel metal stirring paddle 2 inches diameter, thermoregulator, 300-watt heater, thermometer +30 to 70°C in 0.2°C, and Stainless steel platform.

9928-A. Constant Temperature Bath, Circular, complete as above described, with 5 ft. cord and plug. Power consumption 325 watts. For 115 volts, 60 cycles, a.c. .................. 135.10

---

ARTHUR H. THOMAS COMPANY

Laboratory Apparatus and Reagents

WEST WASHINGTON SQUARE PHILADELPHIA 5, PA.
Teletype Service: Western Union WUK and Bell System PH-75
CHEMICAL EVALUATION OF THE FUNCTIONS OF THE LIVER

by

John G. Reinhold

William Pepper Laboratory of Clinical Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pa.

PART I

(A) The Anatomy Of The Liver
(B) Diseases Of The Liver And Biliary Tract
(C) The Chemical Physiology Of Liver Disease
   (1) Carbohydrate Metabolism
   (2) Cholesterol And Lipid Metabolism
   (3) Nitrogen Metabolism

INTRODUCTION

In discussing tests for liver function, an attempt has been made to fit the various practical tests into the larger picture presented by the disturbed chemical physics of liver disease. The practical tests described are those that the author and his colleagues have found to be useful. Such a selection is conditioned by many factors besides the excellence of a given test and technique, and it should not be inferred that alternative methods are inferior. Furthermore, limitations of time and space, the fact that much of the writing was done while on vacation in Mexico two hundred miles from a library, and the undoubted existence of gaps in the knowledge of the reviewer will account for the failure to mention certain contributions.

For further information and a truly comprehensive review, the reader is referred to “Diseases of the Liver, Gall Bladder and Bile Ducts” by S.S. Litchman, the third edition of which appeared this year.

The present review is to be published in three sections. The first is in this issue, and is concerned with a review of the anatomy of the liver, a brief description of its diseases, and a discussion of disturbances in carbohydrate, fat, and protein metabolism. A second section will continue with protein metabolism, the non-protein nitrogen, blood clotting, iron and copper metabolism, detoxification, phosphatase, and bile pigments. The final section will include eye excretion, selection and application of hepatic tests, and the bibliography.

Much of the metabolic activity of the body is centered in the liver. It transforms food into readily usable nutrients, stores such nutrients until needed, releases them into the circulation and regulates their concentrations, and disposes of the waste products of their metabolism. The liver manufactures many substances not available in the food. It detoxifies unwanted materials. It secretes adjuvant digestive processes in the intestine and excretes waste products in the bile. It releases hormones and enzymes into the circulation and regulates the level of hormones from other sources. It forms lymph.

The liver contributes to the production of blood plasma, including substrates concerned with clotting. It aids in regulation of the circulating blood volume. It participates in the resistance to infection. It produces heat.

Before discussing the functions of the liver and means for studying them, a resume of the main facts concerning its anatomy seems appropriate. It is necessary also, to describe the major diseases of the liver in order to define more clearly which chemical studies should be made and the response that may be expected.

THE ANATOMY OF THE LIVER

The liver of a healthy adult weighs 1500 grams on the average and it is by far the largest gland in the body. It consists of lobes which vary in size and differ to some extent in the sources of their different blood supplies. The liver is encased in a membrane of connective tissue. This extends into the liver in the transverse direction of the under surface (porta) in the form of a tree with innumerable branches. This framework of connective tissue supports the parenchymal cells, blood vessels, and bile ducts. The portal vein, hepatic artery, hepatic vein and bile ducts enter the liver through the porta also, and undergo equally extensive branching. In its inner structure the liver consists of lobules, one to two millimeters in diameter. The lobules consist of numerous lobular secretory units, each formed by parenchymal cells surrounding a bile canalculus. Blood reaches the lobules mainly from the branches of the portal vein, but this source is supplemented by arterial blood from the hepatic artery. The blood enters the sinusoids, spaces between cords or sheets of hepatic cells, and passes through them to drain into the central vein of the lobule. The relationship of these structures is shown in Figure 1. (Figure 1 = Figure 352 in Histology, by A.W. Han, 2nd ed. J.B. Lippsmickt, 1953.)

Flow of blood through the liver and the blood supply of the lobules is controlled by an intricate mechanism, with much of it located within the lobule itself (Margrath, B.G., and others, 1951). Recent studies (Elion, 1953) have altered previously accepted concepts of the liver structure by demonstrating that the parenchymal cells are arranged in sheets. Between these are the sinusoidal spaces which make possible direct access of blood to these cells.

The parenchymal cells, the most abundant and characteristic cells of the liver, have both secretory and metabolic functions. Furthermore they have both exocrine and endocrine secretory functions and are arranged so that each cell faces both a duct and a sinusoid containing blood.

Fig. 1. Drawing (at high-power magnification) to show how blood from the portal vein and the hepatic artery (at left) flows into sinusoids, lined by reticuloendothelial tissue, that lie between liver cords and empty into the central vein (right). The way that bile travels in the opposite direction in canaliculi to empty into bile ducts in portal areas is also shown.

Besides the parenchymal cells, the liver contains large numbers of reticuloendothelial (Kupffer) cells which form a lining to the sinusoids. Some estimates indicate that up to one-third of the total number of liver cells are of this type. This potentially hemopoietic tissue is similar to that in bone marrow and spleen. The Kupffer cells have phagocytic properties and are important in connection with hemoglobin breakdown and immunity reactions.

DISEASES OF THE LIVER AND BILIARY TRACT

Disturbances of metabolism occurring in liver disease may be sufficiently severe to jeopardize survival. They may be the result of (1) failure of the parenchymal cells to carry out vital functions because of infections or noxious agents (2) decreased mass of functioning parenchymal cells resulting from disease (3) decreased availability of blood to the liver cells because...
of (a) distortion of the liver architecture by scar tissue, (b) prolonged disturbance of the mechanisms regulating flow of blood in the liver with consequent shunting of blood around the liver or through it, (c) extrahepatic interference with blood supply, (d) impaired nutrition, (e) reaction of other organs to liver damage, e.g., brain, kidney, pancreas, adrenals, gonads, spleen, (f) indigence therapy.

Infective disease of the liver, such as viral hepatitis, is characterized by degeneration and necrosis and regeneration of parenchymal cells as shown by variations in size and staining characteristics. Necrosis and complete disappearance of cells and destruction of the normal architecture of the lobules by scar tissue may follow. Scavenger cells, histiocytes, lymphocytes and plasma cells infiltrate the damaged regions. Edema may occur and together with the disorganization of structure tendency to decrease the blood supply. Regeneration of the parenchymal cells can occur rapidly and produce an astonishingly large mass of cells within as little as 24 to 48 hours. Regeneration is favored by a well-maintained blood supply, and lacking this, fails to occur (Crandley and Baldwin, 1932).

Viral hepatitis ordinarily runs its course within one to three months with apparently complete recovery. It may however, become chronic in about 1 per cent, persisting for many years, or it may have an asymptomatic form. Formerly, viral hepatitis was often mistaken for a disease of the bile ducts and the term 'cachetic jaundice' in the older literature is a result of this confusion.

The term cholangitis hepatitis has been applied by Watson and Hoffer (1945) to a syndrome in which inflammation of the smaller bile passages predominated. It differs in a striking manner in its effect on the chemical composition of the blood from those diseases that involve primarily the parenchymal cells. Chemical changes are similar to those found in biliary obstruction and all of the resources of medical knowledge may be required to make a differentiation.

Deposition of fat in the liver may occur as a part of a general fatiness resulting from overnutrition, as a result of dietary deficiencies, or as an effect of the action of toxic substances. Dible (1951) has recently evaluated the significance of liver fit and has demonstrated experimentally that liver fat tends to be increased in proportion to body fat. Fatty liver resulting from overnutrition has little importance insofar as the function of the liver is concerned. However, deposition of fat caused by toxic substances is evidence of a serious disturbance of hepatocellular function. Among the nutritional deficiencies associated with fatty liver are those of methionine, choline, thiamine, or other extrinsic sources of methyl groups. Low protein intakes may also contribute to the production of fatty livers.

Although liver disease of nutritional origin is uncommon in the United States (if the chronic alcoholic is excepted), it is a major problem in many parts of the world, notably the tropical nations of Africa and Asia, and in the Caribbean area. It may be accompanied by infiltration of fat, necrotic changes and cellular infiltration and in certain instances by accumulation of exudate in the liver. In certain parts of Africa, particularly in the Congo, liver disease may be a major manifestation of nutritional deficiency, in others, cirrhosis has been reported in four of five necroplasias.

Liver damage may occur as a result of severe strains on metabolism associated with many diseases. In infectious mono-nucleosis it may be sufficiently severe to constitute a grave hazard to the patient. Marked jaundice and severe alterations in liver function are seen in such patients. Malaria, lobar pneumonia, typhoid fever, various anemias, syphilis and cholera serve as other examples. Diabetes and thyrotoxicosis also may lead to marked liver damage. Surgical operation and anesthesia cause impairment of liver function in some patients (Parke and others, 1931). Liver failure may occur in pregnancy.

A falling heart and the resulting accumulation of blood in the liver and other visera (chronic passive congestion) may lead to marked impairment of the efficiency with which the liver functions. Hydrops due to other causes also leads to liver damage.

Proliferation of the connective tissue of the liver may result from liver disease of infectious, nutritional, toxic, hypoxic, or neoplastic etiology, or it may occur spontaneously because of diminished blood supply resulting from cirrhotic and other factors. The overgrowth of connective tissue in turn leads to disorganization of the liver structure and this at times to further interference with the blood supply. The end result is a shrunken liver consisting largely of connective tissue, and with a markedly decreased amount of parenchymal, reticulendothelial, and vascular tissue. The designation of portal cirrhosis, atrophic cirrhosis or Laennec's cirrhosis has been used at various times to denote such scarring livers. Although not all scarring livers fit the pathologist's definition of Laennec's cirrhosis, this descriptive term appears to be preferred at present. Laennec's cirrhosis accounts for a large proportion of the liver disease encountered in American hospitals.

Cirrhosis of a completely different etiology, differing also in its morphologic and chemical characteristics, appears after biliary obstruction has persisted for long periods. Known as biliary cirrhosis, it is relatively uncommon. This condition may occur spontaneously also, its etiology being unclear.

Obstruction of the bile ducts often causes jaundice which may be attributed erroneously to liver disease. Its essential to distinguish jaundice due to biliary obstruction from that caused by liver disease or excessive destruction of blood, because obstruction requires surgical treatment, whereas jaundice may be well tolerated by the patient with liver disease or be needed by the patient who is hemolyzing his erythrocytes. Gall stones entering the common bile duct are the usual cause of biliary obstruction. Other causes include neoplastic disease of the ducts, especially of the ampulla of Vater, or carcinoma of the head of the pancreas. Stricture of the ducts may follow infection, surgical exploration or other trauma. Disease of the gall bladder is frequently complicated by liver disease. The pancreas often shows evidence of being involved.

Failure to establish the presence of biliary obstruction and to correct it may lead eventually to biliary cirrhosis.

Carcinoma or other types of neoplastic disease of the liver may or may not be accompanied by jaundice. Often such lesions present few signs to the physician. Obstruction of the bile ducts within the liver by neoplasms presumably brings about the rise in alkaline phosphatase activity in serum which provides one of the few diagnostic aids available.

Damage to the liver may be caused by a large number of chemicals and drugs. Carbon tetrachloride has been extensively used for production of experimental liver damage, and probably has been involved more often than realized as an incriminating cause of clinical liver diseases. Asphault, various solvents, para amino benzoate, testosterone, arsenicals, and others have been implicated. The effect on liver function, as measured by laboratory studies, may resemble that observed in biliary obstruction rather than parenchymal liver disease.

Abcesses and cysts of the liver occurring as a result of infections or parasites generally are too localized and involve too little of the liver substance to bring about significant changes in liver function.

Liver disease may affect the metabolism and functions of other organs. Effects upon the brain are especially noteworthy. Continuing liver disease of maximal severity may eventually lead to loss of consciousness or convulsions, and the characteristic electroencephalographic pattern of the syndrome known as hepatic coma. Hepatic coma is frequently but not necessarily fatal. Recovery may occur spontaneously but also has been attributed to a variety of therapeutic agents. Among treatments reported as successful are: the injection of acetic acid, thiamine phosphate, vitamin B6, multiple B vitamins, glutamic acid and glucose, Exchange transfusion and oxygen therapy also have been used.

Impairment of kidney function commonly accompanies liver disease, and may become a grave problem. The coexistence of hepatic and renal failure is often referred to as the 'hepato-renal syndrome'. Fairgher (1949) has described the deterioration of kidney function occurring in viral hepatitis.
THE CHEMICAL PHYSIOLOGY OF LIVER DISEASE

The list of chemical disturbances observed in liver disease is a long one and will become lengthy as metabolism in liver disease is studied more intensively. Kaisely (1951) has listed 18 major altered chemical functions of the liver with 75 subheadings. Many of these cannot be discussed here for lack of space.

Carbohydrate metabolism.— Studies of hypoglycemic animals by Maun (1927) and his collaborators showed conclusively the vital importance of the liver for maintenance of the blood glucose concentration. Although hypoglycemia is not a common complication in patients suffering from acute paroxysmal liver disease, it does occur in cirrhosis of the liver type with sufficient frequency to require that fasting blood glucose determinations be included in the study of such patients. Blood sugar concentrations as low as 25 mg/100 ml are not uncommon. A diagnosis of inapparent cell damage of the paroxysmal type is occasionally erroneously made in cirrhotic patients because of recurrent hypoglycemia (Conn et al.; Waife (1951) and collaborators showed that insulin resistance occurs in cirrhosis, the fall in blood sugar after a standard insulin injection being delayed as compared with that of healthy individuals. However, hypoglycemia following the insulin persisted for a much longer time in healthy controls. Thus a markedly impaired ability to mobilize glucose in response to hypoglycemia may be deduced. Injection of epinephrine causes a smaller rise in blood sugar of patients with liver disease than it does in healthy subjects (Gell, 1943; Kinsell and associates, 1949). Hillman (1949) reports this test to have doubtful value in the study of liver function.

Glucose administered to patients with liver disease often causes a greater but more persistent rise in blood glucose than it does in healthy individuals, Conn et al.; (Campbell and Tegnam, 1946; Smith, Eltinge, and Selipogon, 1953) have studied the metabolism of fructose and of glucose in patients with liver disease. They found evidence of impaired ability to utilize both, but not of sufficient consistency to enable application as diagnostic or functional tests.

Decreased utilization of galactose in liver disease has provided the basis for one of the earlier tests of liver function (Bauer, 1905). The measurement of galactose excretion in urine originally used has been replaced by measurement of blood galactose concentrations (Alberson, Lockhart and Saley, 1940; Alberson, 1949; Zieve, Hill and Nesbitt, 1950). Colcher, Fiate and Kendal (1946) have described an intravenous galactose tolerance test by which the quantity of galactose removed per minute was found to be markedly decreased in liver disease. The cause of the elevated blood galactose and increased output in urine characteristic of severe liver disease has not been established, but presumably is due to a decreased interference with the enzymatic conversion of galactose to glucose as described by Caputo, Leloir, Cordini and Paladini (1950). An idiopathic defect in galactose metabolism involving a galactose kinase has been studied by Greenspan (1950). The liver is thought to be the source of this enzyme.

Methods for study of disturbances of carbohydrate metabolism in liver disease.— Blood sugar determinations after an overnight fast generally will enable detection of hypoglycemia. A diet very low in carbohydrate accentuates the tendency toward hypoglycemia. (Conn et al. 1938). Glucose tolerance measured by standard three or five hour techniques may be used but, as indicated above, gives little useful diagnostic information. Measurement of phosphate excretion in 24 hour urine also fails to differentiate clearly between the several causes of impaired glucose tolerance. Methods for galactose tolerance are given in the preceding paragraph. Further studies by means of these improved techniques are needed for appraisal of these procedures. The recent literature gives little reason to believe that fructose tolerance tests would be of value in diagnosis of liver disease.

Serum cholesterol and lipids in liver disease.— Recent work has supported the belief that the liver is the principal organ concerned with the metabolism and excretion of cholesterol. The serum lipids often show marked changes in diseases of the liver and biliary tract. Although serum cholesterol concentration and the partition between free and esterified cholesterol is most frequently studied, neutral fat and especially cholesterol esters are of fundamental importance. The recent literature gives little reason to believe that fructose tolerance tests would be of value in diagnosis of liver disease.

Serum cholesterol and lipids in liver disease.— Recent work has supported the belief that the liver is the principal organ concerned with the metabolism and excretion of cholesterol. Cholesterol esters are most frequently studied, neutral fat and especially cholesterol esters are of fundamental importance. The recent literature gives little reason to believe that fructose tolerance tests would be of value in diagnosis of liver disease.

Cholesterol esters may be found in the liver, serum, and feces of patients with liver disease. The concentration of cholesterol esters in the liver, serum, and feces of patients with liver disease is related to the severity of the disease. The concentration of cholesterol esters in the liver, serum, and feces of patients with liver disease is related to the severity of the disease.
termination of esterified cholesterol, the presence of jaundice or of a marked elevation of serum bilirubin serves reasonably well.

The cause of the lowered concentrations of serum lipids characteristic of severe liver disease is not known. Contributing factors include (1) the lowered intake of lipid brought about by preclusion of dietary fats in carbohydrate and low fat in patients with liver disease, (2) decreased synthesis of fat and of other lipids because of reduced mass of parenchymal cells, impaired blood supply and other related mechanisms, leading to impaired efficiency of biochemical transformations, (3) a diminished supply of supplementary factors such as bile, metal, cholesterol, etc., because of diminished intake and decreased synthesis, these together with other factors, leading to (4) deposition of fat in the liver.

The decreased esterification of cholesterol occurring in severe liver disease also is unexplained. It may be a manifestation of a generalized decrease in cholesteryl synthesis, since cholesterolemia of serum is also depressed. Ballon (1950) has pointed out that the intestinal mucosa is an active site for esterification of cholesterol and that it adds by way of the lymph each day twice the amount of cholesteryl ester found in the plasma at any time. The role of the liver may be to supply some factor needed by the intestine for such synthesis. Its regulatory function is unmistakable.

The cause of the elevated concentration of lipid in serum, so typical of biliary obstruction, is also obscure. The bile does not appear to be an important route of lipid excretion. Much of the cholesterol and probably all of phospholipids excreted in the bile is reabsorbed. Balfour (1947) found that the rate of production of phospholipid was increased in biliary obstruction and that the rise in concentration was proportionate to the increase in rate of production. Rosenman, Friedman and Byrns (1952) have postulated that cholesterol concentration in serum rises as a response to an increase in concentration of bile acid (cholesterol). They believe that changes in concentration of the latter are accompanied by changes in serum cholesterol which serves perhaps to counteract the toxicity of cholate for tissues. Byrns, Friedman and Michaelis (1951) find that the liver itself is the source of the extra cholesterol.

The close relationship maintained between free cholesterol and phospholipid might then be expected to lead to increased concentrations of the latter. Information concerning biliary calculi in liver disease is scanty and unsatisfactory. It is to be hoped that recent improvements in sensitivity of the methods for bile acid determination in serum and bile will overcome this deficiency. Studies of fasting bile following release of biliary obstruction in patients allowed to be absent from the bile for a number of days (Radin et al., 1933). The crude methods available in the past for estimating bile acid concentrations in serum indicate that bile acid enters the blood stream to attain concentrations of 10 to 20 mg. per 100 ml. in the presence of biliary obstruction. Elevated values may occur also in liver disease affecting the biliary tract but less prominently, (Sherlock and Wallace, 1943).

Methods for study of disturbances of lipid metabolism in liver disease.— Serum cholesterol and cholesterol ester concentrations may be determined by the methods of Aseel et al. (1952) or of Sperny and Webb (1938). For phospholipid concentrations the method of Zilversmit and Davis (1952) is convenient. A rapid and simple method for detecting total lipid of serum, the phenol turbidity, has been described by Kunkel, Atrens and Eiseinberger (1940).

Phenol Turbidity
Principle.— A reagent containing phenolphthalein with sodium chloride in high concentration reacts with serum lipid to produce turbidity which is proportional to the concentration of serum lipid. Reagents.— Phenol-sodium chloride solution: Dissolve 60 g. of NaCl in about 450 ml. of water. Add 5 ml. of colorless liquefied phenol (90%). Dilute to 500 ml. with water. Store in the cold and discard when it turns yellow. Liquefied phenol is prepared by adding 1 part of water to 10 parts of phenol crystals.

Sodium chloride solution: 0.85 per cent.

Procedure.— Blood is collected from the fasting subject, preferably before breakfast. Measure 5.4 ml. of phenol-sodium chloride solution into a cuvet and place it in a water bath at 25°C. for 5 minutes. Add 0.3 ml. of serum, mix and replace in the water bath for 30 minutes. Measure the absorbancy at 560 m.

For setting the zero, use a blank in which 0.3 ml. of serum are added to 5.4 ml. of 0.85% sodium chloride solution.

Calculation.— Same as described for zinc turbidity. Results are expressed in Shani-Hoagland turbidity.

Interpretation.— Oclusion of the bile ducts, biliary cirrhosis, hepatitis due to poisons, and other conditions in which there is involvement of the biliary tract, such as cholangitis with hepatitis, are characterized by elevated phenol turbidity.

The phenol turbidity, measured together with thymol turbidity, enables allowance to be made for elevation of the latter caused by high serum lipid.

Healthy subjects have been found to have phenol turbidities averaging 20 units. Values exceeding 35 units are observed in only five per cent of fasting healthy subjects, those exceeding 40 units may be considered definitely abnormal.

Nitrogen metabolism in liver disease.— Patients suffering from liver disease tend to lose more nitrogen than they take in. Impaired digestion and absorption of food proteins may be an important contributing factor in some forms of liver disease because of a decreased secretion of pancreatic enzymes caused by associated involvement of the pancreas.

The liver, the principal site for transformation of amino acids by synthesis, transamination, etc., into those forms specifically needed, carries out such transformations less effectively when diseased or otherwise injured. Thus, increased concentrations of amino acids are found in blood and urine in liver disease. Analyses of the distribution of amino acids in the urine of patients suffering from hepatic cirrhosis and other liver diseases by Dunn, et al. (1950) and Gobalsky et al. (1952) indicate that certain amino acids are increased substantially, among them methionine, tyrosine, and tryptophane, and that others are lowered, lysine, histidine, and isoleucine.

In Wilson's disease (hepo-lenticular degeneration) amino acid output in urine is significantly increased whereas little or no change can be detected in concentrations of blood amino acids. Dent and Waelsche (1951) describe six different forms of aminoaciduria occurring in liver disease.

In Wilson's disease (hepo-lenticular degeneration) amino acid output in urine is significantly increased whereas little or no change can be detected in concentrations of blood amino acids. Dent and Waelsche (1951) describe six different forms of aminoaciduria occurring in liver disease.

In Wilson's disease (hepo-lenticular degeneration) amino acid output in urine is significantly increased whereas little or no change can be detected in concentrations of blood amino acids. Dent and Waelsche (1951) describe six different forms of aminoaciduria occurring in liver disease.

In Wilson's disease (hepo-lenticular degeneration) amino acid output in urine is significantly increased whereas little or no change can be detected in concentrations of blood amino acids. Dent and Waelsche (1951) describe six different forms of aminoaciduria occurring in liver disease.

In Wilson's disease (hepo-lenticular degeneration) amino acid output in urine is significantly increased whereas little or no change can be detected in concentrations of blood amino acids. Dent and Waelsche (1951) describe six different forms of aminoaciduria occurring in liver disease.
CALCIAL EVALUATION OF THE FUNCTION OF THE LIVER

These include denaturation of amino acids and of adenylc acid, and synthesis of glutamine. Blood ammonia concentrations in hepatocellular dogs were found to rise rapidly (Gordon, Freeman, and Famer, 1952), continuing earlier work by Bollman and Mann (1930). Interest in blood ammonia in liver disease has been revived recently by the finding that patients suffering from cirrhosis who had received ammonia-containing ion exchange resins often showed signs suggesting those of hepatic coma (Gaddum, Phillips, and Davidson, 1952). Blood ammonia concentrations were substantially increased, Kirk (1936) and others previously have shown that the ammonia content of blood is increased in patients with severe liver disease. Seligson (1953) recently reported that not all patients in hepatic coma had elevated blood ammonia concentrations. A report by Nelson and Seligson (1953) showed that ammonia comes from the portal vein, kidneys, and muscles. In shock the liver fails to remove it completely and the blood ammonia level rises.

Plasma proteins in liver disease. - The liver has a dominant role in plasma protein synthesis. It is the known source of plasma albumin and fibrinogen (Miller, 1935; Watson, Bale, 1951). Probably produced in lesser amounts than fibrinogen involved in the clotting of blood also originate in the liver. It is the source of important components included in the alpha and beta globulins (Roberts, 1952, Roberts and Brunish, 1950). The liver is also involved in synthesis of gamma globulin although there is much evidence indicating that synthesis of gamma globulin is largely extracellular.

Albumin concentrations in serum are lowered in patients suffering from cirrhosis, in viral hepatitis during its clinically active stages, in nutritional liver disease, and in neoplastic disease involving the liver. Many authorities consider it to be among the most dependable measurements available for establishing the presence of liver disease. Numerous other causes of low albumin concentration usually can be excluded without difficulty and (or following) its clinical course. For this purpose it is superior to total serum protein concentration because changes in albumin are commonly masked by an equal and simultaneous rise in globulin so that total protein remains unchanged. The changes occurring in serum proteins of a volunteer in whom viral hepatitis was induced is shown in Figure 2.

The causes of the decreased albumin concentration include (1) impaired synthesis because of decreased mass of parenchymal tissue (2) losses by transudation into ascitic and edema fluid (3) losses by hemorrhage, a frequent complication of cirrhosis (4) increase in plasma volume in cirrhosis (5) low protein intake.

The lowered concentration of serum albumin is one of the factors responsible for the occurrence of fluid accumulation in the cephalic-cholesterol circulation and related tests. A change in constitution of albumin and alpha globulin probably contributes. A second major factor is a rise in concentration of gamma globulin. Yet another variable is a rise in statisizing action associated with biliary obstruction (Ducci, 1950). The physicochemical basis for the flocculation and turbidity tests has been discussed recently by Sailer (1952).

An increase in gamma globulin accounts for much of the increase in total globulin of serum. Whereas in healthy individuals gamma globulin reaches a maximum of 1.5 g/100 ml, in liver disease concentrations double this are common, and concentrations five or more times the normal are not uncommon in some patients with hepatitis. Zimmermann, Heller and Hill (1931) observed 10 percent of serum globulin concentration of 9.9 g/100 ml in a patient with subacute hepatic necrosis. Values as high as this have been encountered on several occasions in the writer's laboratory.

The marked rise in gamma globulin occurring in liver disease is similar to that occurring in many other diseases. Robertson (1950) has described extremely high gamma globulin concentrations as a manifestation of sensitization to drugs, and Carter (1949) described equally high gamma globulin concentrations as a result of trichinosis. Tellum (1948) considers it to be part of a general response to sensitizing agents. The rise is associated with a marked proliferation of plasma cells in bone marrow to as much as 25 per cent or more of the total count. Plasma cells and lymphocytes also accumulate in the liver and other affected areas. These and other observations have led Fangeus (1948), Bjorneboe and associates (1947), and Ehrich (1953) and others to attribute to the plasma cells the formation of gamma globulin. According to their hypothesis the elevation in gamma globulin occurring in response to stressful stimuli, among them liver disease, is a result of the proliferation of this gamma globulin producing tissue. However, Popen (1951), Franklin (1931) and their coworkers have observed changes in the kidney and mesenchymal cells of the liver that correlate with increased gamma globulin concentrations in serum. They believe that these cells are the source of the extra gamma globulin. Yet another explanation has been offered recently by Miller (1953), who believes the diminished synthesis of albumin and other plasma proteins leaves a surplus of amino acids which are converted to gamma globulin outside the liver.

The rise in gamma globulin in many patients suffering from liver disease is accompanied by elevation of beta globulin. Extra protein components not normally observed may appear when electrophoretic separation of serum protein is made at pH 8.6, Martin, 1949. That most frequently encountered is the H protein of Waller (1950) observed in infectious hepatitis. Increased gamma, concentrations were observed by Franklin and associates (1952) frequently in liver disease and rarely in other conditions. These components have mobilities close to that of fibrinogen. Other abnormal components may appear within the gamma and beta fractions.

Fibrinogen appears to be within normal limits or low in the plasma of patients suffering from liver disease (Stefani, 1949). Alpha globulins, particularly alpha2, show a tendency toward lower concentrations than those existing in health. Serum mucoprotein has been found by Greenap et al (1952) to be decreased by hepatitis but increased by metastatic invasion of the liver. Much of the mucoprotein is included within the alpha globulin fraction of the serum protein.

The concentrations of some of the specific proteins included in the alpha globulin fraction also are increased. Serum pseudo-cholinesterase is markedly decreased in many patients with liver disease. Gray, Pollakstein and Heifetz (1941)
showed also that serum amylose activities are decreased (exceptions occur if there is an associated pancreatitis or impaired renal function). Others have reported lowered lipase and esterase activities.

**Methods for evaluating changes in serum protein.** - Practical methods for serum albumin and globulin determinations have been described in a recent article (Fiebig, 1953). Measurements of albumin and globulin concentrations are among the most useful available for the study of liver disease. Zone electrophoresis on paper shows great promise as a method for study of serum proteins of patients with liver disease.

Some patients, especially those with liver damage of moderate degree, do not show significant changes in serum albumin and total globulin concentrations. The quantitative measurement of gamma globulin concentrations may offer some advantage in this connection and the salting-out methods of Wolfson, et al. (1948) or of Jager and Nickerson (1948) are available for this purpose. De la Huesa and Popper (1949) have described a turbidimetric method for measurement of gamma globulin which is rapid although less accurate than the preceding. However, the most widely used methods for detecting changes of the type occurring in serum proteins in liver disease are the semi-empirical methods of turbidity and turbidity tests. More than a dozen of these have been proposed but techniques for only three, the zinc turbidity, thymol test, and cephalin-cholesterol flocculation will be described in the present paper. Further information concerning others and an analysis of their mechanisms, Sizer's (1952) review may be consulted.

**Zinc turbidity.**

(Kunkel (1947) test for gamma globulin)

**Principle.** - Gamma globulins are precipitated by zinc ions in buffered solutions of pH 0.5, and be brought to a measured turbidity. The concentration of gamma globulin may be estimated by measuring the turbidity of the suspended precipitate.

**Reagents.** - Zinc sulfate solution: Weigh accurately 0.480 g. of zinc sulfate hydrate (ZnSO₄.7H₂O). Transfer it to a volumetric flask of 100 ml. capacity and dilute to volume with freshly distilled water. Note: Zinc sulfate hydrate may lose water on standing. Use only well crystallized.

Zinc barbiturate reagent: Weigh 0.283 g. of barbitral and 0.210 g. of sodium barbital. Transfer to a volumetric flask of 1 liter capacity with the aid of sufficient water to dissolve the barbital. Add 5 ml. of the zinc sulfate solution and dilute to mark with freshly distilled water of low carbon dioxide content. Protect the reagent against uptake of carbon dioxide. Test the pH, which should be 7.60. If it differs by more than 0.20 from addition of dilute sulfuric acid or sodium hydroxide. This reagent keeps a month or more, but should be tested periodically for change in pH.

**Zinc barbiturate suspension:** Same as described for the turbidity.

**Procedure.** - Measure 5 ml. of zinc barbiturate reagent into a test tube or cuvette. Place in a water bath at 25°C, for 5 minutes. Add 0.1 ml. of serum using a pipette accurately calibrated to deliver between 0.1 ml. Do not blow out the pipette. Mix. Stopper the tube and allow to stand at 25°C, for 30 minutes. Measure the absorbance at 660 mμ using the reagent for a zero setting. If the result exceeds 20 units, repeat with 0.05 ml. of serum.

**Calculation.** - Zinc sulfate turbidity

\[ C = U \times \frac{S}{V} \]

where U is the absorbancy of the unknown, S of the standardized glass suspension, and V the concentration of the standard in terms of Shaks-Houghland (1944) units.

**Interpretation.** - This method demonstrates markedly elevated concentrations of gamma globulin. It is not sufficiently sensitive to do more than grossly indicate variations occurring within the normal range. Elevated concentrations are the rule in acute hepatitis, cirrhosis of the Lawrence type and certain other types of liver disease. However, comparable elevations of gamma globulin concentrations occur in many other diseases and this lack of specificity must be considered in interpreting the results. The turbidity is elevated in a few patients, particularly those suffering from chronic liver disease when the thymol and cephalin-cholesterol flocculation tests are negative. Thus it finds some use as a supplement to these more sensitive tests. The zinc turbidity often is within normal limits when the thymol and cephalin-cholesterol tests are abnormal, whereas the reverse occurs infrequently.

**Thymol Turbidity and Flocculation.**

**Principle.** - Macleod (1944) discovered that thymol in barbital buffer of low ionic strength added to serum produced marked turbidity in the presence of parenchymatous liver disease. In addition, flocculation often appeared on longer standing.

The thymol Barbitral reagent is saturated with thymol. Temperature and other factors influencing solubility must be considered in preparing the solution. The procedure described below has been developed recently in the William Pepper Laboratory of Clinical Medicine of the Hospital of the University of Pennsylvania by the writer and Miss Virginia Yoron. It enables better control of thymol concentration and pH and yields a more uniform reagent of improved stability.

**Reagents.** - Thymol Barbitral reagent: Transfer 6.0 g. of thymol crystals (colorless) to an Erlenmeyer flask of boric acid glass with a capacity of 250 ml. Weigh on an analytical balance 3.99 g. of barbital and sodium barbital. Heat 1000 ml. of distilled water to boiling in another flask and boil it for about five minutes to remove carbon dioxide. Allow the water to cool to about 95°C, and pour about 300 ml. into the flask on the thymol which will melt and partially dissolve. Add the barbital and sodium barbital and the remainder of the hot (above 75°C) water to the flask containing the thymol. Without delay, stir the flask and mix by rotating vigorously for about five minutes. Allow the solution to cool gradually to room temperature. Transfer the reagent to a volumetric flask of 1000 ml. capacity and dilute to the mark with distilled water. Return the solution to the original flask. Add about 1 g. of thymol crystals. Shake vigorously until the solution becomes clear. Allow the flask to stand at 25°C plus or minus 1°C overnight preferably in a constant temperature bath. Mix again and filter through Whatman No. 1 paper, maintaining the temperature of the solution at or near 25°C.

Test the pH which should be 7.55 plus or minus 0.05. The pH may be adjusted by adding 0.1 N NaOH if the reagent is too acid, or by shaking in the presence of a little CO₂, if too alkaline. Expired air may be used as a convenient source of CO₂.

The optimal temperature at which to keep the reagent appears to be 15°C; however, at a temperature of 25°C the reagent remains unchanged for at least 2 weeks. At temperatures lower than 15°C crystals may separate thus causing lower values for thymol turbidity.

Remove sufficient solution for one day's use and place it in a bath at 25°C, at least 30 minutes before using. Exposure to carbon dioxide should be kept to a minimum. The reagent should be renewed when it becomes opalescent.

**Standards:** Turbidity can be measured either visually or photometrically. The latter is recommended. Colloidal glass suspensions have been recommended (Jones, 1951) for use as standards for thymol turbidity measurements. These may be obtained commercially or be prepared according to the following procedure: A one liter boric acid (pyrex) reagent bottle with glass stopper is filled to about one-fourth its capacity with fragments of clean boric acid glass. The glass fragments are covered with a filled water and agitated vigorously on a mechanical shaker until a milky suspension is produced. The time varies with the type of shaker, rate and force of oscillation, whether the glass has been shaken previously, and other factors. 8 to 20 hours have been sufficient on an ordinary reciprocal shaker. The suspended glass is decanted into a 1000 ml.
CHEMICAL EVALUATION OF THE FUNCTION OF THE LIVER

cylinder and diluted to the mark with distilled water. It is mixed and allowed to stand 14 days. The upper 500 ml. is discarded for use as a stock standard.

Standardization. For this determination Beckman Model DU spectrophotometer has been used. Probably other instruments of comparable quality will be found to serve as well. A trial reading of stock standard is made in the spectrophotometer at a wavelength of 665 mμ; cuvette depth, 10 mm. Water is used as a blank. Sufficient water is added to this aliquot of the stock standard to make the absorbency of the diluted suspension approximately 0.100.

The exact absorbency of the diluted suspension is measured in the spectrophotometer using the conditions specified in the preceding paragraph. A suspension having an absorbency of 0.100, tested in an Evelyn photoelectric colorimeter with a filter of 650 mμ, maximal transmission, 5 ml. aperture, and standard reflector was found to be equivalent to 5.5 Macleod's (1944) units and 6.5 Shank-Hoagland (1946) units. The glass suspension may then be used as a semipermanent standard.

Colloidal glass standards deteriorate slowly but may be used for many months if protected against contamination with soluble organic matter.

For visual comparison, the egg albumin-gelatin-formazine standards of Kingsbury, Clark, Williams and Post (1923) were originally used by Macleod. Satisfactory turbidity standards can be purchased either as colloidal glass suspensions, egg albumin-gelatin-formazine, or as plastic substitutes for the latter.

Procedure. — Measure 6 ml. of thymol-harbaldehyde reagent into a photometer cuvette stopper and place the tubes in a water bath maintaining at 25°C. plus or minus 1°C. Add 0.1 ml. of serum from a pipette that will deliver accurately between marks. (Do not blow out). Stopper the cuvette and mix well. In 30 minutes measure the absorbency in a photometer at 665 mμ. Use a cuvette containing 5 ml. of thymol-harbaldehyde solution for the zero setting. If the thymol turbidity exceeds 20 units, repeat using 0.05 ml. of serum. Multiply the result by 2 when this is done.

Calculation. — Thymol turbidity units U × 2 = where U is the absorbency of the unknown, S of the class standard, and C is the thymol turbidity equivalent of the standard.

The thymol turbidity is consistently within the limits of normal in patients suffering from biliary obstruction, if this is of recent origin. Occurrence of elevated thymol turbidity in a patient diagnosed as having biliary obstruction should cause the clinician to re-evaluate carefully the evidence for the diagnosis. On the other hand, lesions of the biliary tract after a month or more may produce sufficient damage to the liver to cause the thymol turbidity to become positive. Even in these circumstances, however, it is unusual for it to be abnormally high.

The thymol reagent reacts also with serum lipid and significant elevations of thymol turbidity may be caused by serum lipid (Shoy, et al. 1947; Popper, et al. 1948). Such changes probably do not have the same meaning transfar as parenchymal liver disease is concerned as does the "true" turbidity due to the changes in protein. Specimens of blood for thymol turbidity tests collected after a meal rich in fat usually give higher readings than fasting specimens, and blood should be obtained, if possible, with the patient in postabsorptive state. Estimation of serum lipid concentrations by means of the phenol turbidity method of Kunkel has been utilized to evaluate the degree of lipemia and thereby to provide some estimate of the extent of the effect of lipid. However, this reagent fails to discriminate between the various lipid components of serum and their inevitably different reactivity with the thymol reagent.

Thymol turbidity may be increased in any disease characterized by marked elevation of gamma globulin. This may occur quite independently of liver involvement. Under conditions which may show elevated thymol turbidity are multiple myeloma, lymphosarcoma, serum sickness, parasitic infections, and others. Although liver damage may occur in these and other diseases either as an intrinsic part of the disease or as a complication, it is necessary to obtain confirmation of its presence in these circumstances by recourse to other liver function tests not directly dependent on change in serum protein.

Thymol flocculation. — Flocculation occurs more frequently when the thymol turbidity readings are elevated but it may occur when there is little or no rise in turbidity. Clinical experience also suggests that the occurrence of flocculation depends upon some additional factor rather than the production of turbidity (Neele, 1948). In general, the significance of a positive flocculation test is the same as for abnormal turbidity. The flocculation test is less frequently positive than in the turbidity test, however, false negative tests are uncommon and the occurrence of thymol flocculation thus may be accepted with a higher degree of confidence as evidence of liver damage.

The serum of healthy individuals shows no flocculation. Flocculation graded one plus or more therefore, is abnormal.

Visual measurement. — The comparison is made with standards with light coming from behind the observer. Readings may be made directly from the standards, if egg albumin-gelatin-formazine standards are used, the protein equivalent is divided by 50 for Macleod units or 30 for Shank-Hoagland units.

Thymol flocculation. — Decant the turbid solution into a conical centrifuge tube of 15 ml. capacity. Stopper and replace in the water bath at 25°C. until the following day. Examine the solution for the presence of a flocculum and note also the extent to which the supernatant has cleared. If flocculation has occurred, it is graded as 4 plus if the supernatant is water clear, or as 1 plus if the flocculation and clearing of the supernatant are minimal. Intermediate degrees of flocculation are designated 2 plus or 3 plus.

The readings may be made quantitative if, after centrifuging, the supernatants are measured in a photometer or colorimeter.

Interpretation. — Results may be expressed either as Macleod units or as Shank-Hoagland units. One Macleod unit equals two Shank-Hoagland units. Ninety five per cent of a group of healthy subjects tested by the writer and his colleagues were found to have thymol turbidities not exceeding 5.5 Shank-Hoagland units; and 99 per cent were less than 6.6 units when a thymol-harbaldehyde reagent buffered at pH 7.55 was used. The corresponding values for a reagent buffered at pH 7.80 are 4.4 and 5.5 units. The Commission on Liver Disease of the Armed Forces Epidemiological Board has recommended that Shank-Hoagland units be adopted in preference to Macleod units.

The thymol turbidity test ranks high among liver function tests in its ability to reveal presence of liver disease. It is among the tests frequently positive in viral hepatitis, and is particularly useful during the recovery period for evaluation of progress and for detection of carriers of viral hepatitis. Although patients with cirrhosis may show elevated thymol turbidity, often it may fail to become positive in cirrhosis either of the Laennec or biliary type. Neele and associates (1947) introduced the use of the reagent buffered at pH 7.55, claiming improved sensitivity. This has been confirmed by Neele and associates (1950). See also Lotner and Pendleton (1949).
A NOTE ON QUANTITATIVE UROBILINOGEN DETERMINATIONS

BY

BERNARD BALIKOV

Percy Jones Army Hospital, Battle Creek, Michigan

TABLE I

Relation between Concentration of Acetic Acid and pH of Ferrous Hydroxide Filtrates

<table>
<thead>
<tr>
<th>Glacial acetic acid concentration (per cent)</th>
<th>pH of 5 ml. of filtrate</th>
<th>pH of 10 ml. of filtrate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.5</td>
<td>4.4</td>
<td>4.9</td>
</tr>
<tr>
<td>1.0</td>
<td>4.0</td>
<td>4.3</td>
</tr>
<tr>
<td>2.0</td>
<td>3.7</td>
<td>3.9</td>
</tr>
<tr>
<td>3.0</td>
<td>3.5</td>
<td>3.8</td>
</tr>
<tr>
<td>4.0</td>
<td>3.3</td>
<td>3.6</td>
</tr>
<tr>
<td>Feces</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td>6.1</td>
<td>11.6</td>
</tr>
<tr>
<td>0.5</td>
<td>4.0</td>
<td>4.4</td>
</tr>
<tr>
<td>1.0</td>
<td>3.7</td>
<td>3.9</td>
</tr>
<tr>
<td>2.0</td>
<td>3.3</td>
<td>3.6</td>
</tr>
<tr>
<td>3.0</td>
<td>3.2</td>
<td>3.4</td>
</tr>
</tbody>
</table>

negligible amount of urobilinogen was recovered (99% transmittance). Similar results were obtained using 5 or 10 ml. of filtrate for extraction, indicating complete extraction of at least 10 ml. of filtrate.

Determinations of pH over the critical range of 0.5 to 4.0% glacial acetic acid are shown in Table I. A Beckman pH Meter Model G was used for all pH measurements.

Feces Identical experiments were carried out on feces as described for urine, above. Glacial acetic acid concentrations ranged from 0.1 to 10%. From Fig. 1, it can be seen that the optimum concentration of glacial acetic acid is between 0.5 and approximately 1.5%. Here also similar results were obtained using 5 or 10 ml. of filtrate for extraction.

Determination of pH over the critical range of 0.1 to 3.0% glacial acetic acid are shown in Table I.

The experiments were repeated on five separate samples of both urine and feces yielding identical results in each instance.

DISCUSSION

Various references (2, 3) to the methods for extraction of urobilinogen from urine and feces are somewhat vague as to the specific degree of acidification optimum in the procedure. The importance of this aspect of the method has been a matter of some speculation in this laboratory. We were gratified, therefore, to note that optimum extractions were obtained uniformly when acidification of urine filtrates were held rigidly at the end concentrations of 2.0% glacial acetic acid and fecal filtrates, at 1%. We have, therefore, instituted the following modifications of the standard Watson method referred to above.

Urine: Either 5 or 10 ml. of ferrous hydroxide filtrate is transferred to a separatory funnel. Water is added to bring the volume to 40 ml. One ml. of G.P.

* Presently at The Surgical Research Unit, Brooke Army Medical Center, Fort Sam Houston, Texas.
QUANTITATIVE UROBILINOGEN DETERMINATIONS

The above findings have suggested that additional study of urobilinojen at various pH levels and its possible solubility in organic acids would be of value. Such will be undertaken shortly.

It is not surprising that the optimum acid concentration is less for the fecal ferrous hydroxide filtrate than for the urine since the former is less alkaline than the latter.

The significance of the plateaus in Figs. 1 and 2, between acid concentrations of 3 and 4%, is not known.

SUMMARY

A procedure is discussed whereby the optimum extraction of urobilinojen from feces and urine can be accomplished by standardization of the ferrous hydroxide filtrate in the Watson method.

BIBLIOGRAPHY


EUROPEAN MEETING

The French Society of Clinical Biology was host to an international group at a meeting at Monaco on May 28-30. The meeting was held in conjunction with the 30th Anniversary of the discovery of anaphylaxis by Charles Richet and Paul Portier. This discovery took place during a voyage on the yacht of Prince Albert of Monaco, patron of the Oceanic Institute of Monaco and Paris.

Twenty-five papers were presented under the following three headings:
1. Anaphylaxis And Allergy, Dr. Kallos (Swedish) Immuno-Chimie In Allergy; Prof. Sarafini (Recco) and Dr. Halbern (Paris); "The Laboratory Need in Allergic Affections".
2. Laboratory and Diagnostics Of The Lunatic, Prof. King (London) "The Path of the Laboratory in the Diagnosis of Silicosis"; Prof. Deland (Paris) "Anaphylogeny of Silicosis".
3. Endocrinology: Dr. Azerrad and Prof. Agr. Fauvert (Paris) "Comparison of Different Tests of Evaluating Thyroid Funktion".

REVIEW OF CURRENT LITERATURE

ELLENMAE VIERGIVER - EDITOR
CECILIA RIEGEL, C. VON FRITJAF DRABBE, HARRY G. ANRODE

CLINICAL EXPERIENCE WITH SERUM IRON DETERMINATIONS IN THE DIFFERENTIAL DIAGNOSIS OF JAUNDICE, Paul Ecker (Krankenhaus Forst, Lausnitz, Ger.) Z. ges. inn. Med. 6, 21-31 (1953).

Of 52 cases of hepatitis 42 showed an increased serum Fe. In 53 cases of obstructive jaundice only 3 showed an increased Fe.


A modification of the method of Sarney is described. Reproducibility and accuracy are demonstrated. The normal range was found to be 3.5 to 8.5 mg per 100 ml.

ELECTROPHORETIC PROTEIN FRACTIONATION ON FILTER PAPER. M. Netzel (Univ. Marburg/Lahn, Ger.) Plasma (Mlinir) 1, 87-100 (1953) (in German)

A lecture on the method of Osmann and Harrington, practically applied by Knedel.


A rapid and simple method for the determination of total cholesterol in serum is described. Close agreement with the Schenkramer-Speyer method is claimed.


A method for the assay of trypsin is described which is similar to antibiotic tests on agar plates and is based on the diffusion of trypsin on agar-agar gels. The method is simple and exact and allows detection of 0.001 units/ml.


The relation of Cu and Fe in the serum to certain diseases is discussed.


It is suggested that fibrinogen or fibrin be used as a reference standard when determining plasma proteins by the burlet method.

The method of Beassey uses a kerosene-xylene solvent for extracting vitamin A and carotene form serum. This solvent often contains impurities which affect the spectral characteristics. Reducing the solvent over Na then distilling the xylene and kerosene at appropriate temperatures removes the impurities.

NEW STAINING METHOD FOR SERUM PROTEIN FRACTIONS IN PAPER ELECTROPHORESIS. Heinz Reitger (Staatsbad, Esther, Ger.) Naturwissenschaften 39, 451, 1952.

The stain is saturated Fonsen 2R in 50% methanol containing 10% AcOH. Time 10 minutes. The extinction coefficient is proportional to the protein concentration.


Thiamine in biologic materials can be analyzed by conversion to thiochrome with CNBr and taka-dextase. The solution is passed through a searoid column and the fluorescence is measured after elution with butanol.


The Tollem test for galactose is generally unsatisfactory in the presence of xylose or glucose, which produce similar color changes. According to van der Hear (Rec. Trav. chim. 37, 108 (1917)) galactose is the only sugar to form an insoluble o-tolylidrazone (m.p. 178°).

Poweweather recommends the following procedure. Pipette into a test tube one ml. of urine, previously evaporated if necessary to a sugar concentration of one percent, as determined by analysis. Add 0.2 ml. of freshly prepared 5 percent solution of o-tolylidrazone hydrochloride. Dissolve approximately 20-30 mg. of sodium acetate in the mixture and add 10 ml. ethanol. Heat for a few minutes at 90-100° and filter off the precipitate. Evaporate the filtrate at 45° to remove all alcohol. Cool, add one drop of distilled water, mix and examine the drop on a microscope slide. Typical rod-like needles of the hydrazones are observed within a few minutes if galactose is present. Glucose may yield carboxylic crystals after 2-3 hours. Fructose also produces carboxylic crystals, usually more rapidly than glucose. These may be readily distinguished from the galactose o-tolylidrazone. J.I.C.


Coproporphyrins I and III were administered intravenously to rats. In the normal animal, no increase in urinary excretion occurred; approximately one-fifth of the injected material was excreted in the feces. In acute liver injury due to carbon tetra-chloride, there was an increase in uranine coproporphyrinexcretion with a relative reduction in the amount excreted in the feces. In rats with chronic liver injury due to a chloro-deficient diet, virtually none of the injected porphyrin could be recovered in either urine or feces.


A total of 14 individuals with active hemophilia were studied. An electrophoretic anomaly, called a "globulin" was found in the plasma of all 14. The same anomaly was also observed in 8 members of hemophilic families who were not active bleeders. The electrophoretic anomaly was seen in females as well as in males.


Human prostatic tissue is excised with 0.05% NaCl. The supernatant fluid, after centrifugation is dialyzed against water. The supernatant from this is frozen and dried. The lyophilized crude material is fractionated with EDTA and the final ppt. again dialyzed and lyophilized. The prep. varied in activity, the purest hydrolyzing the equivalent of 26 mg P under the conditions used, and the best prep., hydrolyzing the equiv. of 75 mg P. Assay for alkaline phosphatase was negative. No P caused 95% inhibition.

C.R.


Organic material is removed from all blood, urine or gastric contents by digestion with HNO3 and H2SO4 while, at the same time, Hg is converted to the divalent form. In this acid solution, Hg combines with dithizone to form a yellow-orange complex that is soluble in CHCl3. The dithizone complex, plus any uncombined dithizone, is estimated colorimetrically; the Hg complex is destroyed by an acid-potassium iodide reagent and the total uncombined dithizone is determined. The difference between the two readings is a measure of the Hg dithizionate and hence a quantitative measurement of the Hg present in the sample. The advantages of the method are: as little as 0.2 micrograms of Hg can be determined; 24 hr. is required; all reagents are soluble in one hr.; the samples required may be as little as 2 ml. of blood, 2 gm. of tissue, or 5 ml. of urine or gastric contents; the use of acid potassium iodide gives a sharp color reaction and eliminates interference by practically all other metals that react with dithizone at a pH of less than 1.

C.R.


A modified colorimetric method is presented in which FeCl3 is added to the H2SO4 prior to the oxidation of lactic acid by ACH. After the addition of veronal a stable green color results.

H.A.


The modern concept of blood clotting is reviewed.

H.A.

DETERMINATION OF BARBITURATES. ULTRAVIOLET SPECTROPHOTOMETRIC METHOD WITH DIFFERENTIATION OF SEVERAL BARBITURATES. Leo R. Goldblum (Army Med. Service Graduate School, Washington, D.C.) A simple, specific and rapid ultraviolet spectrophotometric method for the determination and identification of barbiturates in described. The method may be applied to blood, urine, and tissues.

H.A.


The method of Hallewells and Kratzs (C.A. 24, 8401) is said to be quicker, more sensitive, and requires less specimen than that of Folin and Wu.

H.A.
URINARY AND FECAL COPEROPHRYN EXCRETION IN RATS: II. RESULTS IN NORMAL AND CARRIER ANIMALS.

P.W. Hoffbauer, C.J. Watson, and G. Schwartz (Dept. of Medicine, Univ. of Minnesota School of Medicine, Minneapolis), Proc. Soc. Exp. Biol. & Med. 89: 228-232, 1953.

Increased excretion of urinary coproporphyrin has been used as a sensitive index of liver function impairment. Because of the extensive use of white rats in the study of liver damage, the excretion of coproporphyrin by this animal was investigated. The data obtained using normal animals are presented. E.V.

TUBELESS GASTRIC ANALYSIS BY USE OF INSOLUBLE SALTS WITH EXCENSUS 100X.

H. Miller (Dept. of Medicine and Biochemistry, the Strong Memorial Hospital, Rochester Municipal and Genesee Hospitals, Univ. of Rochester School of Medicine and Dentistry, Rochester, N.Y.), Proc. Soc. Exp. Biol. & Med. 83: 483-487, 1953.

A method for the determination of gastric acidity without intubation is described. The amount of quinine in the first 2-hour urine excretion after the oral administration of quinine carbonate is used to determine the presence of gastric hydrochloric acid secretion. E.V.

SAFETY OF IMMUNE SERUM GLOBULIN WITH RESPECT TO HOMOLOGOUS SERUM HEPATITIS.


Immune serum globulin produced by the cold-ethanol method from proved infectious plasma failed to produce hepatitis in 10 normal subjects inoculated with 5 ml. each. E.V.

URINARY AND FECAL COPROPHRYN EXCRETION IN RATS: II. RESULTS IN EXPERIMENTAL LIVER DAMAGE.

P.W. Hoffbauer, C.J. Watson, and G. Schwartz (Dept. of Medicine, Univ. of Minnesota School of Medicine, Minneapolis), Proc. Soc. Exp. Biol. & Med. 89: 228-232, 1953.

Despite the severe degree of liver involvement, no consistently significant increases were observed in the excretion of urinary or fecal coproporphyrin in rats fed a diet or thioacetamide. Average 2- to 4-fold increases, however, were observed in the ratio of urinary to fecal coproporphyrin. Transitory increases in urinary coproporphyrin fecal coproporphyrin ratio following acute exposure to carbon tetrachloride vapor were observed. The injection of lead in rats produced a striking increase in urinary coproporphyrin excretion. E.V.


Cold only in underwear, twenty healthy young men were exposed to a temperature of 45-50°F for a period of 90 minutes. There was a significant elevation in the mean concentration of serum potassium but no significant changes in the mean serum concentrations of total magnesium, sodium, or calcium. No correlation was observed between the changes in the electrocardiogram and the changes in the concentration of serum potassium. E.V.


A new colorimetric method for the determination of a urinary metabolite of acetyl-CoA is described. The use of the precipitation with 2-mercaptoethanol as a quantitative determination of this metabolite is described. E.V.

CHARACTERISTIC INDIVIDUAL ELECTROPHORETIC PATTERNS IN HUMAN, P. Hamel, M.M. Decourse, and P. Hoegger (Conner Research Laboratories, New England Center Hospital, and Dept. of Medicine, Tufts College Medical School, Boston), Proc. Soc. Exp. Biol. & Med. 83: 429-431, 1953.

The detailed examination of the contours and fine architecture of the electrophoretic patterns of human plasma in different individuals may reveal considerable dissimilarities between persons, even in those cases where the relative amounts of plasma components are similar. These dissimilarities are discussed in detail. E.V.


A new colorimetric method for the determination of hyaluronic acid is described. The use of the precipitation of acid polysaccharide with hemoglobin at pH 8.4 and conversion of the precipitated protein to ferricenium cyanide is described. E.V.

PROPIPETTE

- Avoids mouth pipetting
- Measures precisely — to 0.01 cc.
- Quick, complete control
- Holds set level indefinitely
- Simple to use
- Fits any pipette only $6.90 ea.

Money refunded within 10 days!

MAIL THIS COUPON NOW!

Instrumentation Associates, Dept. P. 3
138 Haven Avenue, N.Y.C. 32, N.Y.

Please send ............... PROPPIPETTES

@ $6.90

□ Amount enclosed □ Change added for N.Y.C. delivery

Name: ....................
Organization: ...........
Address: ...................
City: ........ Zone: State: ...........
PUBLISHERS' CORNER

Academic Press, Publishers, announces the completion of plans for a new journal, RADIATION RESEARCH, the official organ of the Radiation Research Society, Dr. Titus C. Evans, College of Medicine, State University of Iowa, is the Managing Editor of the new periodical.


RADIATION RESEARCH will publish original articles dealing with all phases of radiation research to promote the integration of the disciplines of physics, chemistry, biology, and medical research as they are concerned with the effects of radiation on matter. The term "radiation" is here used in its broadest sense and specifically includes ionizing, ultraviolet, infrared, and visible radiations.

RADIATION RESEARCH will help radiochemists, chemists, biologists, and medical researchers to keep abreast of new developments in a rapidly expanding field that has numerous ramifications and a widely scattered literature.

Volume 1, Number 1 of this bimonthly publication is scheduled for release in February 1954. Among the papers to be published in the early issues are a group devoted to radiation chemistry (with A. O. Allen, E. S. G. Barron, H. A. Dewhurst, W. M. Garrison, J. L. Magee, H. R. Raymond, A. H. Samuel, and B. M. Weeks as authors), radiation biology, and medical research (with L. H. Grey and Raymond E. Zirkle as authors) a Symposium on Physical Measurements in Radiobiology (with papers by G. Failla, U. Fano, Payne S. Harris, L. D. Marinelli, and Burton J. Moyser).

Information about subscriptions may be obtained from the publishers, Academic Press Inc., 125 East 23 Street, New York 10, New York (U.S.A.).

The third volume in the "Biochemical Preparations" series was published this month by John Wiley & Sons, 440 Fourth Avenue, New York 16, N.Y.

Following the established format, the new book gives accurate detailed methods for the preparation of twenty-four compounds used in biochemical research. The information supplied for each compound again includes: principle, starting material, procedure, properties and purity of product, and methods of preparation.

The material in Volume 3 has been prepared and carefully checked for accuracy by a group of biochemists under the editorship of Edward E. Snell, professor of chemistry at the University of Texas.

The Advisory Board of the series includes: W. Manusfield Clark, Hans T. Clarke, Max S. Dunn, A. Baird Hastings, William C. Ross, Donald D. Van Slyke, Hubert R. Vickery, and Vincent du Vigneaud.

Also staffed by specialists in the field, the Editorial Board consists of: Eric G. Ball, Herbert E. Carter, Joseph S. Fritton, Arthur Kornberg, Henry A. Lardy, Albert L. Lehninger, Carl G. Niemann, David Shafiz, Earl W. Sutherland, Jr., and W. W. Westerfeld.

Volume 3 of "Biochemical Preparations" contains 128 pages and is priced at $3.50. The first two volumes, edited by H. E. Carter and Eric G. Ball respectively, are available at $3.00 each.

Biochemists who have preparations that are appropriate for future volumes are invited to submit suggestions to Professor W. W. Westerfeld, Department of Biochemistry, State University of New York in Syracuse, who is now editing Volume 4.

Volume 33 in the well-known "Organic Syntheses" series was published in September by John Wiley & Sons.

This latest addition to the annual publication supplies the most convenient methods for the preparation of 40 reactions, contributed by 64 chemists. In accordance with established procedure, each reaction has been thoroughly checked in the laboratory before publication.


"Organic Syntheses," Volume 33, contains 115 pages and is priced at $3.50.

SOUTHERN CALIFORNIA SECTION

Robert J. Foster, Ph.D., Research Fellow, Kerckhoff Biological Laboratories, California Institute of Technology, discussed "Enzyme Kinetics", October 6-meeting at the Cedars of Lebanon Hospital, Los Angeles.

M. E. Morton, M.D., Ph.D., Chief, Radiology Unit, Long Beach Veterans Administration Hospital, spoke on his work on "The Determination and Interpretation of Serum Thyroxin Levels", November 3 at the Hollywood Presbyterian Hospital, Los Angeles.

Robert W. Fink, Ph.D., Research Biochemist, Department of Investigative Medicine, Long Beach Veterans Administration Hospital, discussed "Chromatographic Techniques", at the December meeting held at the Los Angeles County Hospital.

In his September 1 address at the Los Angeles County Hospital, Joseph R. Goodman, Ph.D., Biochemist, Long Beach Veterans Administration Hospital, spoke on the fundamental principles in the operation of the analytical centrifuge. The derived equations of Svedberg were given, and general theories were discussed. Considerable time was devoted to the description of the operation of the Spinco models, and some of the problems and techniques of evaluation were discussed. The analytical spinning head and the cells were exhibited and their functions described. The methods and techniques of Gofman's lipoprotein analysis were presented, and the limitations and implications of this kind of data were mentioned. The talk was followed by a discussion period which was led by Kenneth Johnson who has been working on ultracentrifugal problems at the California Institute of Technology.
GUIDE TO ETHICS GOVERNING THE CONDUCT OF CLINICAL CHEMISTS

A tentative Code Of Ethics was published last year (C.C. 4 July 1952) so that the AACC membership would study the articles and contribute suggestions. After reviewing all suggestions and revisions, the articles and sections were approved by The National Executive Committee, September 1953. The following is now the official Code Of Ethics of the American Association Of Clinical Chemists, Inc.

Article I
DEFINITIONS AND GENERAL CONSIDERATIONS

WHAT CONSTITUTES CLINICAL CHEMISTRY

Section 1. Clinical chemistry is that branch of chemistry which deals with the composition of the secretions, excretions, concretions and fluids of the human body in health and disease, and the chemical composition and metabolism of cells and tissues. Also the search for the presence of substances (or their derivatives) given for diagnostic or therapeutic reasons and the search for poisons (or their derivatives) are properly included in the field of clinical chemistry.

WHAT CONSTITUTES A CLINICAL CHEMIST

Section 2. Any individual equipped by education and experience to engage in the practice of clinical chemistry as defined above shall be considered a clinical chemist.

RESPONSIBILITY OF THE CLINICAL CHEMIST

Section 3. The profession of clinical chemistry, as an adjunct to the profession of medicine, has as its ultimate responsibility the welfare of the public. The clinical chemist shall use to the best of his ability his scientific skills and knowledge to the benefit of all men without regard for racial or religious origin.

EDUCATION AND EXPERIENCE

Section 4. The clinical chemist shall have as his goal the acquisition of the best available education and experience in chemistry. He shall strive to constantly enlarge and improve his knowledge.

RELATIONSHIP TO THE MEDICAL PROFESSION

Section 5. The clinical chemist shall deal with the medical profession at all times at the highest professional level. The compensation by the patient for chemical services shall include no rebates or commissions to any person for solicitation or referral of analyses.

RELATIONSHIP TO THE PATIENT

Section 6. The clinical chemist shall perform no service to the patient except on advice or prescription from any licensed practitioner of the medical arts. All reports and discussion of chemical findings shall be only between the chemist and the physician in charge.

Article II
PUBLICATION, PATENTS, AND ADVERTISING

DISSEMINATION OF SCIENTIFIC INFORMATION

Section 1. The clinical chemist shall freely discuss with his fellow chemists and with scientists in related fields, advances in the science of clinical chemistry. To withhold information for personal gain shall be considered unethical. This Section shall not apply to information classified by a government agency for reasons of national security.

PUBLICATION OF RESEARCH FINDINGS

Section 2. An obligation to publish, after critical evaluations, new knowledge pertaining to the science of clinical chemistry obtained through research or other observations, shall be acknowledged.

ADVERTISING AND PUBLICITY

Section 3. The clinical chemist shall not use, or allow his name to be used, in advertising directed to the public. Professional announcements shall be brief, dignified and consistent with accepted customs in medical and allied fields. The clinical chemist shall not seek publicity, yet he shall recognize the right of the public to have access to information concerning the public health and welfare. Publication of a scientific article or book shall precede the release of such material to the lay press. Because of the danger of misinterpretation, he must use restraint and great caution in releasing information having direct or therapeutic implications.

PATENTS AND COMMISSIONS

Section 4. The application of discoveries and developments in Clinical Chemistry, directly affecting public health and welfare, should not be limited by unreasonable restrictions for personal gains to the Clinical Chemist.

Article III
OBLIGATIONS AS A CHEMIST

ACCURACY OF CHEMICAL ANALYSES

Section 1. The clinical chemist shall have as his goal the attainment of the highest precision and specificity that existing procedures permit.

REPORTING OF SIGNIFICANT FIGURES

Section 2. The analyst shall not report figures or decimal places that lack significance.

CRITICAL SURVEY OF METHODS

Section 3. It shall be considered inadequate practice for a clinical chemist to use any procedure that has not been adequately studied in his own laboratory.

REPLICATES AND RECOVERIES

Section 4. The systematic use of controlled procedures, such as replicates and recoveries, shall be considered indispensable to good practice.

RESULTS OF UNCERTAIN MAGNITUDE

Section 5. The clinical chemist shall not report any result of uncertain magnitude of error, unless this uncertainty is clearly made known to the recipient of the report.
ARTICLE IV
INTERPRETATION OF RESULTS
RELATIONSHIP TO THE PHYSICIAN
Section 1. The clinical chemist shall, at the request of the physician in charge of the patient, outline to the physician the significance of any chemical findings, and suggest further determinations that would aid the physician in making a diagnosis or prognosis. The clinical chemist shall under no circumstance transmit to the patient either the results or the interpretation of the results. The clinical chemist shall receive no compensation from the patient for interpretation of results to the physician.

ARTICLE V
THE CLINICAL CHEMIST AS AN INDIVIDUAL

A SCIENTIST AT ALL TIMES
Section 1. The clinical chemist shall conduct himself as a scientist at all times.

HIGH REGARD FOR MEDICAL PROFESSION
Section 2. The clinical chemist shall hold in high esteem the profession of medicine, to which he is an adjunct.

RELATIONSHIP WITH ANALYSTS
Section 3. The clinical chemist shall carefully supervise the analysts working in his laboratory. He shall train these workers to the best of his ability, encourage them to attain the highest professional competence, and teach them by word and example to adhere to the ethical standards herein outlined.

PUBLICATIONS AND COLLABORATORS
Section 4. The clinical chemist shall contribute as much as possible to research and advancement of his specialty. He shall encourage those working in his laboratory to do likewise. He shall accept as collaborators whenever possible the junior members of his staff and encourage these members to contribute to the science of clinical chemistry. He shall to the best of his ability assist physicians and other scientists by fully collaborating in their efforts to advance medical science.

ARTICLE VI
CONCLUSION
The ethics of the clinical chemist shall at no time be inferior to the standards long prevailing in the medical profession. The outline here presented can act only as a general guide, and shall be periodically reviewed and revised. It is for the individual to judge his professional conduct in the light of his obligation as a scientist to serve mankind.

NEW APPARATUS
ELECTROPHORESIS-DIFFUSION INSTRUMENT
A new unit-type electrophoresis-diffusion instrument featuring double sensitivity in an optical system based upon double passage through the cell, is described in a new folder identified as Form 8726.00. Suggested for application in the analysis, study, and identification of electrically-active particles in biological and chemical research fields, the new unit is illustrated in detail. Descriptions are given of the five individual optical facilities included: the automatic photography and controls; the controlled-temperature bath; the refrigeration unit; the rotary cell turret which accommodates three cell assemblies; and the automatic, calibrated, and electronically-regulated current supply. Specifications are given on dimensions, weight, electric power, and cell power-supply characteristics.

Specialized Instruments Corporation
682 O'Neill Avenue
Beltmoc, California

CORRECT ADDRESS FOR EMPLOYMENT CLEARING HOUSE
Members seeking personnel or those wishing to change their present affiliations should send all pertinent details to:
Joseph I. Routh, Ph.D.
Professor, Biochemistry
Iowa City, Iowa

At the recent Annual Meeting, Professor Routh consented to initiate the Association Employment Clearing House, and will keep an active file of all employment opportunities.

BOOK REVIEWS

This book is the first in a series that has as its goal the consolidation of information in organic quantitative non- elemental analysis. In this first book, sections are devoted to methods for the quantitative determination of hydroxyl, alkoxy, alpha-epoxy, carbonyl, acetal and organic sulfur groups. In addition, discussions are included for the determination of alpha-hydroxy and carboxymethyl compounds and dimethyl succinates and the use of spectrophotometric functional group analysis in the petroleum industry. Each section includes a brief discussion of the various procedures available for the particular determination. This is followed by detailed discussion of the more important methods, the laboratory procedure and a description of the apparatus. Micro as well as macro techniques are discussed.

The best feature of this book is the critical evaluation of the various procedures showing in detail the limitations of the methods and the modifications that the authors found necessary in the application of the procedures in their own laboratories.

This book should prove of value as a critical source of information on quantitative procedures for both the organic and analytical chemist.

CORRECTION
In reporting the lecture “The Chemical Detection Of Barbiturates And Physiological Antagonists To Barbiturates” by Dr. Theodore Koppanyi (C.C. 5, 75 (1953)), attention has been called to the following addenda.

Under Procedure: the third sentence should read “The cobaltion acetate and lithium hydroxide reagents are added to each of the three test tubes: 0.05 cc to A, 0.1 cc to B and 0.15 cc to C.”
This filter, developed by Dr. G. R. F. Hilson and Dr. S. D. Elek, of the Department of Bacteriology, St. George's Hospital Medical School, London, is often most valuable in routine and experimental laboratory work when it is necessary to obtain sterile filtrates of small quantities (up to 5 ml) of liquid with the minimum possible loss by absorption in the filter element.

It will be seen from the sectional diagram above that the filter consists essentially of a flanged metal tube with its upper part separated by a Seitz E.K. pad from the lower, the overall dimensions permitting it to be used in place of a 15 ml centrifuge bucket.

In use, the metal holder is first loaded with the glass receiving tube, and the filter pad is placed on the stage followed by the washer. The cup is then screwed down loosely, and the whole filter autoclaved. The cup is then screwed down firmly, thus tightly compressing the pad between the stage and the washer.

Filtration is completed in 15 to 25 minutes at about 2,500 r.p.m. depending upon the viscosity of the fluid. The loss by absorption is not more than 0.4 ml (8%, of 5 ml).

In addition to the general efficiency of this centrifuge filter, it has the great advantage that it can be made up and sterilised as a unit. Cat. No. 69052, 12.00 each

The great advantage of the centrifugal Gradocoll Filter over the positive-pressure and suction types is that whatever pressure is required can be very simply achieved by alteration of the speed of rotation.

Capacity is about 4.5 ml and all metal parts of the apparatus which come into contact with fluid are made of stainless steel.

The filter is assembled loosely with the membrane in position and sterilised by intermittent steaming. Alternatively the glass tube, together with all metal parts, can be sterilised by dry heat. Autoclaving is used for the rubber washers and the filter discs are steam sterilised. Assembly should preferably be done under ultra-violet light. The required filtration pressure is obtained by adjusting according to a nomogram (supplied with the apparatus) which correlates speed, the centrifuging radius of the discs and the depth of fluid in the cup with the pressure developed.

Cat. No. 69062. 19.60 each
Model 69328 (filters) - 1.90 per doz.

Distributed by

J. BEEBER CO., INC.
838 BROADWAY, NEW YORK, N. Y. - AL 4-3509
1109 WALNUT ST., PHILADELPHIA, PA. - KI 5-0646
AMERICAN ASSOCIATION
of
CLINICAL CHEMISTS INC.

1954 DIRECTORY
HONORARY MEMBERS

Blatherwick, Norman R., (1949)
416 Sea View Avenue, Daytona Beach, Fla.

Bloel, Walter R., (1950)
School of Medicine and Dentistry, University of Rochester, Rochester, N.Y.

King, E J., (1951)
Postgraduate Medical School, University of London, London, England

Noyons, E. C., (1951)
Byllysveldsingel 16, Nijmegen, Netherlands

Shaffer, Philip A., (1952)
Professor of Biochemistry, Washington University School of Medicine, St. Louis 10, Mo.

Van Slyke, Donald D., (1951)
Brookhaven National Laboratory, Brookhaven, N.Y.

A

Abernethy, Raymond J., (1950), Coroner’s Office, 106 Hall of Justice, Los Angeles 12, Calif.

Ackerman, Philip, (1949), 6541 Marquette Street, St. Louis 9, Mo.


Alper, Carl, (1950), Department of Biochemistry, Hahnemann Medical College, Philadelphia 2, Pa.

Anderson, Marie A., (1949), University Hospital, Baltimore 12, Md.

Anderson, Dorothea E., (1951), 564 Arlington Avenue, Elmhurst, Ill.

Anderson, Pearl R., (1949), 1205 Forest Glenn Road, Silver Springs, Md.


Ammen, Frank J., (1950), 281 Skillman Street, Brooklyn 5, N.Y.

Aronsohn, Joseph S., (1953), 266 Arbaray, Jamaica Plain, Mass.

Amodei, Harry G., (1953), Children’s Hospital, 19th and Bainbridge, Philadelphia 46, Pa.

Applegate, Harold E., (1950), 408 South Main Street, Hightstown, N.J.

Appleton, Harold D., (1949), Chemistry Department, Metropolitan Hospital, Welfare Island 17, N.Y.

Armbruch, Bernard H., (1952), 5900 Hamilton Street, Hyattsville, Md.

Arredondo, Emilio Guido, (1953), 427 South Governor, Iowa City, Iowa.

Ashe, E. Gregory, (1953), R.R. #5, Box 149, Decatur, Ill.

B


Balkov, Bernard, (1952), Surgical Research Unit, Brooke Army Medical Center, Ft. Sam Houston, Texas

Ballard, Grace, (1949), 925 No. 13 St., Milwaukee 3, Wis.


Barlow, James E., (1951), 276 Franklin St., Framingham, Mass.

Barrett, Paul D., (1949), Edsel B. Ford Institute for Medical Research, Henry Ford Hospital, Detroit 2, Mich.

Basinski, Daniel H., (1950), Department of Laboratories, Henry Ford Hospital, Detroit 2, Mich.
Brunner, Ruth L., (1950), 5311 The Paseo, Kansas City 4, Mo.
Burke, Foster W., (1952), 2821 Valencia Drive, Santa Barbara, Calif.
Burns, Robert A., (1953), 11910 Cavell Street, North Hollywood, Calif.
Bushner, Richard J., (1952), 434 England Street, Lundsdale, R. I.

C
Cogan, Ralph N., (1951), 730 W. State St., Trenton, N.J.
Campbell, Frank M., (1953), Sharon Mkt. Road, Box 187, Sharon, Conn.
Carbone, Lynn, (1953), 2441 Wentworth Avenue, Chicago, III.
Carmichael, Emmet B., (1952), Medical College, University of Alabama, Birmingham, Alabama
Carr, Herbert O., (1950), 2315 Charlemagne, Long Beach 15, Calif.
Caryn, Mildred (1949), 66 Bay State Ave., West Somerville 44, Mass.
Carr, Julius J., (1948), Chemistry Laboratory, The Mount Sinai Hospital, New York 29, N.Y.
Carr, Mari H., (1950), 7018 Broadmoor, Overland Park, Kansas
Carroll, Ralph M., (1950), 118 West 3 St., Sadalsia, Mo.
Carson, Richard M., (1950), Carson-Seeds, Inc., 11 St. Mary's Street, Dayton, Ohio
Cavazza, Helen C., (1951), 110 Dwight Street, New Haven, Conn.
Chaney, Albert L., (1949), 1503 East Chevy Chase Drive, Glendale 6, Calif.
Chen, Chih-Chen, (1953), Northwestern University Medical School, 303 East Chicago Avenue, Chicago 11, III.
Chernat, Joseph M., (1950), 136-21 Roosevelt Avenue, Flushing, N.Y.
Chesley, Leon C., (1949), 45 Dubomt Street, Valley Stream, N.Y.
Chew, Dorothy, (1952), DePaul Hospital, Norfolk 5, Va. (Last known address)
Clements, James J., (1951), Laboratory Department, Reading Hospital, West Reading, Pa.
Cohen, Milton M., (1952), 165-33 Hillside Avenue, Jamaica 3, N.Y.
Cohn, Clarence F., (1951), Michael Reese Hospital, Chicago 16, Ill.
Connolly, Valentine J., (1950), U. S. Marine Hospital, Staten Island 4, N.Y.
Cosner, Thomas H., (1951), St. Joseph Hospital, 21 Peace Street, Providence, R. I.
Cooper, David Y., (1952), B. O. O., N. M. C., Room 213, Bethesda, Md. (Last known address)
Corbet, William E., (1953), University of North Dakota Medical School, Grand Forks, N. Dak.
Cramer, Frank B., (1950), 472 North Bedford, Beverly Hills, Calif. (Last known address)

D
Danielson, Bernice H., (1950), 6956 South Jeffery Avenue, Chicago 49, Ill.
Danielson, Wayne H., (1949), Children's Hospital, Denver 18, Colo.
Davidson, M. Moira, (1953), 207 Wissahickon Road, North Wayne 91, Mass.
DeFrates, Joseph, (1950), Department of Biochemistry, Hahnemann Medical College, 235 North 15 Street, Philadelphia 2, Pa.
Delaney, Kathleen, (1949), Chemical Laboratory, Stanford Hospital, Stanford, Conn.
Diamond, Bernard L., (1951), Tabor Medical Bldg., 351 Tabor Road, Philadelphia 41, Pa.
Dickerson, Henry C., Jr., (1954), 1825 Savannah Street, S.E., Washington, D. C.
Dickman, Albert, (1950), 1415 West Erie Avenue, Philadelphia 40, Pa.
Diederich, Mary M., (1951), Mount Mary College, Milwaukee, Wis.
Dietz, Mary R., (1952), 4023 Brooklyn, Kansas City, Mo.
Diets, Albert A., (1950), Toledo Hospital, Institute of Medical Research, Toledo 6, Ohio.
Dobkin, Gerald B., (1952), 1495 Morris Avenue, New York 57, N.Y.
Dobkin, Jacqueline L., (1949), 1495 Morris Avenue, New York 57, N.Y.
Downey, Gladys J., (1953), 506 Grandview Courts, Iowa City, Iowa
Drake, Miles E., (1952), Vineland State School, Vineland, N.J.
Dryer, Robert Leonard, (1951), 1040 West Michigan Street, Indianapolis, Ind.
Dubes, Clyde A., (1949), 1814 West Boulevar, Los Angeles 19, Calif.
Dubin, Alvin, (1951), 4180 Marine Drive, Chicago, III.
Dubinsky, Eli H., (1952), 5 Payson St., Boston 21, Mass.
Dubowski, Kurt M., (1950), Department of Laboratories, Iowa Methodist Hospital, Des Moines, Iowa
Duffy, Anne M., (1949), 85 Gravenhurst Street, Brookline 46, Mass.

E
Eichen, Seymour, (1953), 315 E. 196 St., Bronx 58, N.Y.
Elden, Anne B., (1953), 3721 Sheppard Street, Apr. 5, Brentwood, Md.
Elkon, Bruno, (1952), 83-13 Bay Parkway, Brooklyn 14, N.Y.
Ellis, Helen, (1951), 7683 North Rogers Avenue, Chicago 26, III.
Emmanuel, E. D., (1953), Community Hospital Laboratory, Fairfax, Mo.
Enoch, Isle Maria, (1950), 828 Green Street, San Francisco, Calif.
Epstein, Raphael, (1949), 2244 86 St., Brooklyn 14, N.Y.
Ettinger, Richard H., (1953), St. Luke's Hospital, Chicago, III.
Eyles, Ruth, (1951), 1371 Avon Ave., S.W., Atlanta, Ga.

F
Feldman, Donald, (1953), Laboratories, V.A. Hospital, Brooklyn 9, N.Y.
Fenichel, Richard L., (1951), 9360 Genesee Avenue, Detroit 6, Mich.
Finch, Edmund P., (1950), Box 251, Veterans Administration Hospital, Hines, Ill.
Flore, Joseph V., (1951), 154 Underhill Avenue, White Plains, N.Y.
Fitzgerald, John T., (1949), Clinical Laboratory, Mercy Hospital, Portland 3, Maine
Flatcher, J. Wesley, (1951), 1321 Meridian Avenue, South Pasadena, Calif.
Fax, Charles L., Jr., (1952), New York Medical College, 1 East 105 Street, New York 29, N.Y.
Frame, Elizabeth G., (1953), 4757 Chevy Chase Drive, Chevy Chase 15, Md.
Freeman, Monroe E., (1950), 3850 Tipton Road, N.W., Apt. 206, Washington, D. C.
Friedman, Howard S., (1950), 613 S. Oregon St., Tampa, Fla.
Friedman, Max M., (1948), Lebanon Hospital, New York 57, N.Y.
Frieser, Rudolf G., (1950), Interchemical Corporation, 432 West 45 Street, New York, N.Y.

G
Gaebler, Oliver H., (1949), Institute for Medical Research, Henry Ford Hospital, Detroit 2, Mich.
Gardner, Eli, (1951), 71-47 Austin St., Forest Hills 75, N.Y.
Gast, Joseph H., (1951), Baylor University College of Medicine, 1200 M.D. Anderson Blvd., Houston 25, Texas
Gawron, Oscar, (1950), 1014 North Clair Street, Pittsburgh 4, Pa.
Getchell, Gloria, (1952), 454 South Robertson Blvd., Los Angeles 48, Calif.
Glauberman, Rachel S., (1949), 1685 Topping Avenue, New York 57, N.Y.
Goeckel, Henry J., (1950), 191 North Larch Avenue, Cranford, N.J.
Golden, Walter R. C., (1949), Stanford Hospital, Stanford, Conn.
Goldenberg, Harry, (1950), Department of Biochemistry, Hillside Hospital, Box 39, Glen Oaks, N.Y.
Golding, Margaret M., (1950), 4451 North Fairway Drive, Sherman Oaks, Calif.
Goldstein, Gilbert, (1950), 144-03 79th Avenue, Kew Gardens Hills, N.Y.
Golub, Murray, (1950), Oswego County Laboratory, Oswego, N.Y.
Goodman, Carlyle W., (1950), Route 1, Lynchburg, S.C.
Gottfried, Sidney P., (1949), 53 Bennett St., Fairfield, Conn.
Gottesman, Gertrude Y., (1953), 315 East 68 Street, New York 21, N.Y.
Gouve, Susan C. J., (1953), 5419 Potomac Terrace, Route 2, Falls Church, Va.
Green, Saul, (1951), 612 Rugby Road, Charlestowne, Va.
Greenholtz, J. Jr., (1949), Bath-Ell Hospital, Rockaway Parkway and Ave. A, Brooklyn 12, N.Y.
Greenspan, Joseph, (1950), 575 Ocean Avenue, Brooklyn 26, N.Y.
Greinsteing, Alexander L., (1949), 3725 Laurel Avenue, Brooklyn, N.Y.
Gross, Milton, (1953), Margaret Hague Maternity Hospital, 88 Clifton Place, Jersey City 4, N.J.
Gross, Sol, (1950), 622 Watkins St., Brooklyn 12, N.Y.
Grosscup, Charles G., (1949), Abington Memorial Hospital, Abington, Pa.
Gubernick, Isadore, (1949), 139-19 34 Road, Flushing, N.Y.
Guggletlo, Arthur E., (1952), V. A. Hospital, 200 Holcombe Blvd., Houston, Texas (Last known address)

H
Hainline, Adrian Jr., (1952), Cleveland Clinic, 2020 East 93 Street, Cleveland 6, Ohio
Hamilton, Lyle Howard, (1953), 200 Riverside Park, Iowa City, Iowa
Hamill, Robert H., (1950), Department of Physiological Chemistry, Temple University Medical School, Philadelphia 40, Pa.
Hanou, Albert, (1949), Omega Chemical Company, 111 Herricks Road, Garden City Park, N.Y.
Harris, James C., (1950), Bldg. 2, Apt. A6, Slocum Heights, Syracuse, N.Y.
Harris, Lewis E., (1949), 1414 Ridgeway Road, Lincoln, Neb.
Havery, Thomas S., (1951), Princeton Hospital, Princeton, N.J.
Heftmann, Erich, (1950), Room 205, Bldg. 2, National Institute of Health, Bethesda 14, Md.
Hertov, Lucien D., (1950), 490 Post Street, San Francisco 2, Calif.
Hill, Robert M., (1950), 4200 East 9 Street, Denver, Colo.
Hiller, Almo, (1953), Rush Department of Biochemistry, Presbyterian Hospital, 1753 West Congress Street, Chicago 12, Ill.
Hisey, Alan, (1950), School of Chemistry, University of Alabama, University, Ala.
Hoch, Hans, (1953), 408 Park St., Charlottesville, Va.
Hodes, Morton E., (1950), 275 Fort Washington Avenue, New York 32, N.Y.
Hodges, La Verne R., (1953), Trace Metal Laboratory, Peter Bent Brigham Hospital, Boston 15, Mass.
Hoefel, Mary Louise, (1949), Grove Coeur, Mo.
Holman, Martha H., (1949), Morton Hospital, Taunton, Mass.
Hollings, Hilt F., (1951), School of Public Health, University of California, Berkeley, Calif.
Holmes, Frederic E., (1949), 6515 Blue Ridge Avenue, Cincinnati 13, Ohio
Hoobler, Icete M., (1950), 660 Frederick Street, Detroit 2, Mich.
Horkin, Samuel M., (1953), 6423 Wilshire Boulevard, Los Angeles 48, Calif.
Horneff, Joseph A., (1952), 433 Maple Avenue, Haddonfield, N.J.
Horti, Michael, (1949), 98-27 Jamaica Avenue, Richmond Hill, N.Y.
Hubbard, Roger S., (1951), 330 North St., Buffalo 1, N.Y.
Hudson, A. E. A'Court, (1952), Edgewood Apartments, Goldsboro, N.C.
Hummel, John Philip, (1953), 124 Conklin Lane, Iowa City, Iowa

Ilke, Stephanie J., (1949), 210 East 03 Street, New York 28, N.Y.
Irish, Oliver J., (1953), Veterans Administration, Vermont Avenue and H Street, N.W., Washington 25, D.C.

J

Johans, B., (1949), 8 Webster Avenue, New Rochelle, N.Y.
Jock, Crystal E., (1952), 3425 N.W. 25 Street, Oklahoma City, Okla.
Jenkins, Esther E., (1951), 426 West 3rd Street, Mansfield, Ohio
Johnson, Edith C., (1949), 53 Mt. Everett Street, Dorchester, Mass.
Johnson, Kenneth D., (1949), 4816 Ocean View Boulevard, La Jolla, Calif.
Johnson, Richard C., (1954), Department of Pathology, Iowa Lutheran Hospital, Des Moines, Iowa
Jones, Ralph W., (1950), Laboratory, Baptist Memorial Hospital, San Antonio, Texas
Jones, Vera J., (1950), 3804 Cherry Street, Kansas City 4, Mo.

K

Kaneb, Eugene, (1950), 4736 North Troy Street, Chicago 25, Ill.
Kanelesi, Louis, (1950), 24 Johnson Avenue, Newark 8, N.J.
Kanter, Saul L., (1950), 1049 Willow Road, Monticello Park, Calif.
Kaplan, Alex, (1950), Department of Biochemistry, Michael Reese Hospital, Chicago 16, Ill.
Kaser, Margaret M., (1949), Veterans Administration Center, Wood, Wis.
Katz, Albert B., (1950), Hackensack Clinical Labs, 269 Passaic Street, Hackensack, N.J.
Katz, Elaine J., (1950), Argonne National Laboratory, P.O. B. 299, Lemont, III.
Katz, Joseph, (1953), Norwalk Hospital, Norwalk, Conn.
Kay, Hazel T., (1922), 11389 Segrell Way, Culver City, Cal.
Kay, Heinz T., (1952), 13389 Segrell Way, Culver City, Cal.
Kayser, Sidney, (1954), 404 N. 12 Street, Richmond, Va.
Kennett, Arthur G., (1949), Bender Hygienic Laboratory, 136 South Lake Avenue, Albany 3, N.Y.
Kibbick, Andre C., (1949), N. Y. U. College of Medicine, 477 First Avenue, New York, N.Y.
Kier, Lawrence C., (1950), R.R. 1, Iowa City, Iowa
Kingsley, George R., (1949), 621 Bonhill Road, Los Angeles 49, Calif.
Kirby, John K., Sr., (1950), Chemical Laboratory, University Hospitals, Iowa State University, Iowa City, Iowa
Kittenger, Alice L., (1950), 1229 Second Street, Santa Monica, Calif.
Klein, Berhard, (1949), 129 Patton Blvd., New Hyde Park, N.Y.
Klein, Margaret, (1949), 1043 Bergen St., Brooklyn 16, N.Y.
Klein, Sam, (1949), 144 Helen Terrace, Newark 8, N.J.
Kleiner, Israel S., (1949), Department of Biochemistry, New York Medical College, 1 East 106 Street, New York 29, N.Y.
Knouse, Reiner Wm., (1951), 2458 Wingate Drive, Chamblee, Ga.
Knowles, Marjorie, (1953), 1701 Massachusetts Ave., N.W., Washington 6, D.C.
Knudsen, Arthur, (1949), Albany Medical College, Albany, N.Y.
Kochel, Leonore H., (1953), St. Luke's Hospital, Bethlehem, Pa.

Kajima, Inoyo, (1951), 725A Eighth Avenue, Honolulu 16, T.H.
Kazanjian, Stephen J., (1951), 12415 Connecticut Avenue, Silver Spring, Md.
Krasnov, Frances, (1949), 405 East 72 St., New York 21, N.Y.
Kreisel, Kathryn K., (1950), 7327 - 50th Avenue, N.E., Seattle 5, Wash.
Kuechler, George, (1949), 1137 East Jefferson Street, Elizabeth, N.J.
Kurzweil, Blossom D., (1951), 161 West 71 Street, New York, N.Y.

L

Landy, Edgar, (1951), 53 Huntington Avenue, North Dartmouth, Mass.
Lasker, Stiglund, (1950), 566 E. 170 St., New York 57, N.Y.
Lauber, Annie E., (1949), 115 Sullivan Street, New York 12, N.Y.
Laughlin, Alice M., (1950), 1060 No. Willard Street, Burlington, Vt.
Lawrence, Penni A., (1952), 455 Ocean Avenue, Brooklyn 26, N.Y.
Leithart, Howard C., (1949), ISC O-63460, 4th Med. Field Lab., Landstuhl Army Medical Center, APO # 180, Postmaster, New York, N.Y.
Levani, Esther M., (1951), 3950 North Fairwell Avenue, Apt. 105, Milwaukee, Wis.
Leonard, Reid H., (1953), 2544 Escambia Avenue, Pensacola, Fla.
Lesnyk, I1ona D., (1949), 74 Fenwood Road, Boston 15, Mass.
Leutonoff, Theodore V., (1951), Clinical Laboratory, U. S. Veterans Hospital, Coatesville, Pa.
Ley, Stanley, (1949), University Hospital of Cleveland, 2065 Adelbert Road, Cleveland 6, Ohio.
Levine, Victor, (1949), 144-14 87th Road, Jamaica, N.Y.
Ley, Irving, (1950), 3434 Knox Place, Bronx 67, N.Y.
Lewadowski, Joseph T., Jr., (1953), 93rd Medical Group, Castle Air Force Base, Calif.
Lewis, George T., (1949), Department of Biochemistry, School of Medicine, University of Miami, Coral Gables 45, Fla.
Lewis, Merle Lovell, (1950), 1615 Fletcher Avenue, South Pasadena, Calif.
Lewy, Luci, (1949), 860 Riverside Drive, New York 32, N.Y.
Lingle, Albert F., Jr., (1953), 19 Grand Avenue, Tacoma Park, Md.
Longwell, Barnard B., (1953), 4800 Gibson Blvd., Albuquerque, N.M.
Loughhead, Ruth, (1950), 6120 Kimber, Chicago 37, Ill.
Lovell, Clarence E., (1950), 441 Hickman Road, Des Moines, Iowa
Lowenstein, Bertrand E., (1949), 550 Bickell Avenue, Miami 32, Fla.

M

Macchiaverna, Mario, (1954), 27 Chelsea Ave., Newark, N.J.
Ming, Charles, (1952), 721 S. Valley Ave., Vineland, N.J.
Ming, Mary F., (1952), 721 S. Valley Ave., Vineland, N.J.
Mirkin, Abraham, (1950), 226 E. 12 St., New York 3, N.Y.
Mishkind, Daniel L., (1949), Chemistry Department, Jewish Memorial Hospital, Broadway at 145 Street, New York, N.Y.
Mizuno, Nobuke, (1951), 1282 Hewitt Ave., St. Paul 4, Minn.
Molnar, Julius, (1950), 211 E. 19 St., New York 3, N.Y.
Molnar, Nicholas M., (1950), 211 E. 19 St., New York 3, N.Y.
Morland, Ferrin B., (1951), Baylor Medical College, Houston 25, Texas
Morgenstern, Stanley, (1952), 142 South 9th Street, Brooklyn 11, N.Y.
Mozer, George B., Jr., (1953), R.D. 2, Box 193, Stolz Road, Library, Pa.
Mulay, Ambudas S., (1950), National Cancer Institute, National Institute of Health, Bethesda 14, Md.
Mundy, Roy L., (1953), 10426 Julep Ave., Silver Springs, Md.
Meadow, Harold, (1950), Johnson & Johnson, Research Foundation, New Brunswick, N.J.

N
Narlow, Guy, (1953), 203 Brown Ave., Quebec 6, Canada
Nathanson, Samuel, (1948), Rockford Memorial Hospital, Rockford, Ill.
Nicholls, Rufus A., (1952), 1454 Dean St., Brooklyn 13, N.Y.
Nix, Mary J., (1951), 4931 N.E. Glisan, Portland 13, Ora.
Noblet, Sidney, (1953), 981 Elizabeth Terrace, Elberon, N.J.

O
Olsen, Norman S., (1950), Research Laboratory, Thayer V.A. Hospital, Nashville 5, Tenn.
Oser, Bernard L., (1949), Food Research Laboratories, 48-14 33rd Street, Long Island City, N.Y.
Osgood, Harlow S., (1930), Swedish Hospital, Seattle 4, Wash.
Owen, Charles A., Jr., (1952), Mayo Clinic, Rochester, Minn.

P
Palmo, Anthony V., (1951), V.A. Hospital, Clinical Laboratory, West Haven, Conn.
Pandit, Dorena, (1931) 610 W. 143 St., New York 31, N.Y.
Papageorge, Evangeline T., (1950), School of Medicine, Emory University, Ga.
Parker, Gene Hays, (1951), USAF (MSC), 3595 Medical Group, Nellis Air Force Base, Las Vegas, Nev.
n
Pastewka, Juliana, (1932), 431 East 4th St., Erie, Pa.
Pnubisineni, Peace, (1953), 33 Paddle Lane, Levittown, Pa.
Poul, Wool, (1953), University Hospitals, Iowa City, Iowa.
Ponamlo, Ralph, (1951), Rockford Memorial Hospital, Rockford, Ill.
Ponkin, Harold J., (1949), Lohey Clinic, Boston, Mass.
Porter, Elina, (1932), 42 Owen Avenue, Lonsdowne, Pa.
Porter, Margaret C., (1949), Columbia Hospital, Milwaukee, Wis.
Petersen, Ralph E., (1952), N. I. M. O., National Institute of Health, Bethesda 14, Md.
Pierce, Harold B., (1950), University of Vermont, College of Medicine, Burlington, Vt.
Pinell, Jack D., (1932), 3470 Cannon Place, New York 63, N.Y.
Pitka, Isadore, (1952), V. A. Hospital, Long Beach, Calif.
Pitkin, Joseph, (1932), 6228 S. Kedvale, Chicago 29, Ill.

...
Pollard, C. B., (1949), 240 Lehigh Hall, University Station, Gainesville, Fla.
Pomerene, Elisabeth, (1949), 3646 Rolliston Road, Shaker Heights 20, Ohio
Portnoy, Seymour, (1951), 4762 Rorer Street, Philadelphia 20, Pa.
Powell, Marchelle H., (1949), Chemistry Laboratory, Mayo Clinic, Rochester, Minn.
Power, Onie H., (1950), 6644 Hilandale Road, Chevy Chase 15, Md.
Preissler, Paul W., (1949), 3709 Juniata Street, St. Louis 16, Mo.
Puckett, Robert F., (1953), P.O. Box 93, Fort Boker, Calif.
Purcell, May K., (1950), V. A. Hospital, Goatesville, Pa.

R

Real, Margaret Anne, (1953), 1205 East Burlington Street, Iowa City, Iowa
Reichman, George A., (1951), Hollywood Presbyterian Hospital, 1322 N. Vermont Ave., Los Angeles, Calif.
Reiner, Miriam, (1948), D.C. General Hospital, Massachusetts Ave. & 19th St., S.E., Washington, D.C.
Reinbold, John G., (1949), Pepper Laboratory of Clinical Medicine, University of Pennsylvania, Philadelphia, Pa.
Reinstein, Harold, (1949), 19 Bay Street, Boston 15, Mass.
Remer, F. M., (1950), 209 Greenwich Ave., Greenwich, Conn.
Remnie, Norma R., (1950), 5311 N. Winthrop St., Chicago 40, Ill. (Last known address)
Rempp, Donald G., (1952), Henry Ford Hospital, Detroit 2, Mich.
Resseler, Mary J., (1951), 419 Wood Bldg., Benton, Ill.
Reyes, Felix M., (1930), V. A. Hospital San Patricio, 15 San Juan, P.R.
Rhodas, J. Cecil, (1950), Medical Arts Laboratory, Jenkintown, Pa.
Rice, Eugene M., (1953), 1831 Yorktown Road, Cincinnati, Ohio
Richardson, Edwin M., (1950), Delaware Hospital, 501 West 1st Street, Wilmington, Del.
Riedel, Paul A., (1949), 35-15 84 Street, Jackson Heights, N.Y.
Riegel, Cecelia, (1950), Lenox Hill Hospital, City Line and Lancaster Ave., Overbrook, Philadelphia, Pa.
Rivera, Jose A., (1950), Brooks Army Hospital, Fort Sam Houston, Texas
Rockenmacker, Morris, (1950), Harbor General Hospital, Torrance, Calif.
Roe, Joseph W., (1950), 1335 H. St., N.W., Washington, D.C.
Rogers, Hazel C., (1950), Training Officer, School of Medical Technology, V. A. Center, Wilshire and Sawtelle Blvds., Los Angeles 25, Calif.
Rohs, Wayne G., (1953), 1016 Diana St., Iowa City, Iowa
Romis, Harry, (1950), 811 Coffey Ave., For Rockaway, N.Y.
Roseman, Saul, (1950), Department of Pediatrics, Bobst Memorial Hospital, 920 East 59 Street, Chicago 37, Ill.
Rosenberg, Abraham, (1949), 1235 Kearney Avenue, Bronx 61, N.Y.
Rosenthal, Henry L., (1953), Rochester General Hospital, Rochester, N.Y.
Ross, George, (1949), 38 Gun Hill Road (West), New York 67, N.Y.
Rothstein, Robert, (1953), 1856 71st St., Brooklyn 4, N.Y.
Routh, Joseph L., (1950), Department of Biochemistry, Iowa State University, Iowa City, Iowa
Rubin, Martin, (1949), Department of Pathology, School of Medicine, Georgetown University, Washington 6, D.C.

S

Sacher, Herbert J., (1953), 1322 Sage St., Far Rockaway, N.Y.
Sacks, Ruben R., (1950), Corson-Sacks, Inc., 11 St. Mary's Street, Dayton, Ohio
Sagin, Jerome P., (1950), 6702 Wells Parkway, University Park, Md.
Saifer, A., (1949), Jewish Sanatorium & Hospital for Chronic Diseases, Brooklyn 35, N.Y.
Saltzberg, Gertrude, (1953), 57 Hanson Place, Brooklyn 17, N.Y.
Sample, Albert B., (1949), 508 Baird Road, Merion, Pa.
Samuelson, George S., (1951), 64 73rd St., Brooklyn 9, N.Y.
Sandin, Mary D., (1950), 1068 42 St., Des Moines 11, Iowa
Sanadhik, Daniel E., (1953), 8309 Cool Spring Lane, R.P.O., Hyattsville, Md.
Sapsin, Stanley, (1951), 1416 Sarazen Dr., Alhambra, Calif.
Schaffer, Roscoe R., (1950), 7265 S. Orizaba Avenue, Downey, Calif.
Schahs, Otto, (1949), 3503 Prytania Street, New Orleans 15, La.
Scharf, Charlotte O., (1951), 116 East 91 Street, New York 28, N.Y.
Schattner, Fred, (1949), 126 W. 91 St., New York 28, N.Y.
Schein, Arnold H., (1950), Department of Biochemistry, College of Medicine, University of Vermont, Burlington, Vt.
Scherf, Frieda, (1950), 145 E. 22 St., New York 10, N.Y.
Schoenhorn, Harold, (1952), 1099 Brighton 6th Street, Brooklyn 25, N.Y.
Schottelius, Dorothy D., (1953), Box 686, Iowa City, Iowa
Schrafft, William, M., (1950), 50 Locust Avenue, New Rochelle, N.Y.
Seligson, David, (1949), 4200 Parkside Avenue, Philadelphia 4, Pa.
Shaffer, Elmer L., (1950), 208 N. State St., Trenton 8, N.J.
Shapiro, Panny, (1949), 467 Central Park West, New York 25, N.Y.
Shapero, Seymour L., (1950), 122 South Broadway, Yonkers, N.Y.
Sharrant, Henry, (1954), 2641 North Spaulding Avenue, Chicago 47, Ill.
Shepherd, James A., (1954), Department of Neurology, General Hospital, State University of Iowa, Iowa City, Iowa
Sherman, Burton S., (1953), 831 Nastrand Avenue, Brooklyn 25, N.Y.
Sherman, Marion K., (1951), 738 Lynn Falls Parkway, Melrose, Mass.
Shelton, Marvin R., (1951), V. A. Hospital, 921 N.E. 13th, Oklahoma City, Okla.
Shukovsky, Carroll F., (1949), V. A. Hospital, 1065, 300 East Roosevelt Road, Little Rock, Ark.
Thompson, Herbert E., (1951), Youngstown Hospital Association, North Side Unit, Youngstown 4, Ohio.
Thompson, Jerry, (1953), 6817 Georgia Avenue, N.W., Washington, D.C.
Thompson, Vera A., (1952), 850 Lincoln Place, Brooklyn, N.Y.
Thompson, Donald E., (1950), 931 Vine St., Paso Robles, Cal.  
Tanks, David Bayard, (1953), 633 Highland Avenue, Ottawa, Ontario, Canada.
Touche, Joseph C., (1953), 902 Moloney Clinic, University of Pennsylvania Hospital, Philadelphia, Pa.
Tribby, Charles A., (1950), Fairfield Laboratory, 2163 Main Street, Bridgeport 6, Conn.

V
Vanderwey, Margaret, (1951), 147 Garber Street, Chambersburg, Pa.
Van Loan, Edward J., (1949), V. A. Hospital, Louisville 2, Ky.
Veres, Michael M., (1953), 123-25 82nd Avenue, Kew Gardens 15, N.Y.
Vieregge, Elliott E., (1949), Ayer Clinical Laboratory, Pennsylvania Hospital, Philadelphia 7, Pa.

W
Wabnitz, Charles H., (1949), 514 Oxford Place, Louisville 7, Ky.
Wang, Chi Choy, (1950), Veterans Administration Hospital, Hines, Ill.
Ward, Arnold G., (1950), Los Angeles County Hospital, 1200 North State St., Los Angeles 13, Calif.
Washington, John R., (1952), 3810 Medical Group, Maxwell AFB, Montgomery, Ala.
Waterman, Charles L., (1950), 5736 South Parkway, Chicago, Ill. (Last known address)
Wayne, Richard S., (1952), 576 Eastern Parkway, Brooklyn 25, N.Y.
Webster, Marion E., (1952), 1218 Missouri Avenue, N.W., Washington 11, D.C.
Weisberg, Harry F., (1950), Mt. Sinai Medical Research Foundation, Chicago 8, Ill.
Weisberg, Jerry, (1952), 17 F Sumnyside, Kansas University, Lawrence, Kan.
Weiss, Elizabeth H., (1951), 41 Bear Ave., Trenton 10, N.J.
Weissbecker, Ludwig, (1953), 9-23 Thayer Street, New York 34, N.Y.
Weissman, Milton, (1949), 830 Bronx River Road, Yonkers, N.Y.
Wells, Louise, (1953), 103 Yard Parkway, Kansas City, Mo.
Wenger, Arthur Winter, (1951), 510 Douglas Street, Salt Lake City, Utah.
Werner, Maxine, (1951), 1237 South Fourth Street, Alhambra, Calif.
Westover, Laea, (1953), 703 South Berendo, Los Angeles 5, Calif.
Wheeler, Joanna X., (1950), Box 116, Veterans Administration Hospital, Hines, Ill.
Wheeler, Thomas E., (1952), 6660 Hillendale Road, Bethesda, Md.
GEOGRAPHIC LISTING

ALABAMA
Cormichael, Emmet B.
Hisey, Alan
Washington, John R.

ARIZONA
Bennett, Helene Thomas

ARKANSAS
Shukers, Carroll F.

CALIFORNIA
Abarnathy, Raymond J.
Allen, Gordon A.
Anderson, Vivian L.
Aronson, Albert
Bergen, William R.
Berkman, Sam
Bischoff, Fritz E.
Buhle, Foster W.
Burns, Robert A.
Carne, Herbert O.
Chaney, Albert L.
Colman, Roger Dixon
Cromer, Frank B.
Dubbs, Clyde A.
Enach, Isle Maria
Fletcher, J. Wesley
Gatell, Gloria
Goldwater, William H.
Goodman, Joseph R.
Henry, Richard J.
Hertlet, Lucien D.
Hollinger, Nell F.
Horkin, Samuel M.
Johnson, Kenneth D.
Kanter, Saul L.
Koy, Hazel T.
Koy, Hainz T.
Kingsley, George C.
Kittenger, Alice L.
Kowaldowski, Joseph T., Jr.
Lewis, Merle Lavelle
Lobstein, Otto E.
MacKay, Eaton M.
Mohr, John R.
Mortuccio, Frank R.
McKee, William E.
Mehr, Silvio E.
Pierce, L.F.
Piteisky, Isadore

Puckett, Robert F.
Reifman, George A.
Rochanacker, Morris
Rogers, Hazel C.
Sazin, Stanley
Schafftar, Roscoe R.
Sobal, Charles
Solow, Harry
Sterling, R. E.
Sycheff, Vladimir M.
Theore, Donald E.
Thore, Arnold G.
Wertman, Maxine
Westerover, Leola
White, Jerome M.
Wick, Arne N.

COLORADO
Danielson, Wayne H.
Fisher, Robert M.

CONNECTICUT
Backer, Sidney
Campbell, Frank M.
Cavallaro, Helen C.
Dalenay, Kathleen
Goldman, Walter R.
Gottfried, Sidney P.
Katz, Joseph
Kolos, Anthony V.
Lerner, F. M.
Sieginfroth, Dorothy A.
Tibby, Charles L.

DELAWARE
Richardson, Edwin M.

DISTRICT OF COLUMBIA
Bradford, Duke C., Jr.
Dickerson, Henry C., Jr.
Ferguson, Monroe E.
Irwin, Oliver J.
Knowlton, Marjorie
Kozlak, Stephen J.
Kramer, Bayle D.
Reiner, Miriam
Ross, Joseph H.
Rubin, Martin
Spearing, Celia W.
Stull, Arthur

Sudduth, Herschel C.
Thompson, Jerry
Webster, Marion E.

FLORIDA
Blatherwick, Norman R.
Friedman, Howard S.
Lewis, George T.
Leonard, Reid H.
Lowenstein, Bertrand E.
Pfaller, C. B.

GEOGRAPHIC LISTING

ILLINOIS
Anderson, Dolores E.
Asher, E. Gregory
Balfour, Samuel
Baron, Eleanor
Bond, Epperson S.
Byers, Walter H.
Coolidge, Lynn
Chapin, Childe
Cohn, Clarence
Danielson, Berne H.
Dubin, Alvin
Elliot, Helen
Erdinger, Richard H.
Firman, Robert R.
Finch, Edmund P.
Hiller, Alma
Kneubuehr, Eugene
Kaplan, Alex
Katz, Elaine J.
Kemp, C. R.
Laughhead, Ruth
MacFadden, Douglas A.
McDonald, John N.
McDonald, Hugh J.
Melville, Robert Seaman
Mills, Elizabeth H.
Natelson, Samuel
Owen, Seward E.
Pannill, Ralph
Plaxton, Joseph
Poll, John F.

remmle, Norma R.
Rice, Mary J.
Roseman, Saul
Shorten, Henry
Stewart, Gordon S.
Song, Chi Che
Watkins, Hannah L.
Wheelan, Joanne X.
Weisberg, Harry F.
Zorn, Elmer M.

INDIANA
Dryer, Robert Leonard

IOWA
Arrendondo, Emilio Guido
Downey, Gladys J.
Dubowski, Kurt H.
Hamilton, Lyle Howard
Hummel, John Philip
Johnson, Richard C.
Kier, Lawrence C.
Kirby, John K., Sr.
Lovell, Clarence E.
Mary, Mary George
Mercedes, Mary
Paul, William D.
Reed, Margaret Anne
Rohse, Wayne G.
Routh, Joseph I.
Sands, Mary D.
Schottisius, Dorothy D.
Sheppard, James A.
Stettner, Max M.
Summers, Dwight M.
Turner, Elvin E.

KANSAS
Carr, Marie H.
Grosdidier, Helen M.
Kahn, J. D.
Weber, Clarence J.
Weisberg, Jerry

KENTUCKY
Van Loan, Edward J.
Wobnitz, Charles H.

LOUISIANA
Golding, Margaret M.
Schaeles, Otto